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To my family 
 
  
 
 
 
 
 
 
  
 
” Reflux is an old hat: now that we have a reliable  
operation to fix it, it is a boring subject to talk about.”  
1974 Sir David Innes Williams 
 
  
  
Abstract 
Background: Vesicoureteral reflux (VUR) is a pathological back-flow of 
urine from the bladder to the ureter and renal pelvis. VUR is associated 
with an increased risk of urinary tract infections (UTI) and renal damages. 
Infants with congenital high-grade VUR (hVUR) often have dysplastic 
kidneys with diffuse parenchymal defects and a bladder dysfunction with 
enlarged bladder and poor emptying ability. Spontaneous resolution of 
VUR with increasing age is common in lower grades of VUR, but is rarely 
seen in high-grade VUR. The goal of all VUR treatment is to prevent UTIs 
and minimize the morbidity related to investigation and treatment. Surgical 
intervention (SI) – endoscopic treatment (ET) or open surgery – can be 
indicated in case of repeated UTI recurrences or progress of renal damages 
during antibiotic prophylaxis. 
The aim of this research project was to investigate whether hVUR in 
infants can be treated with endoscopic injection, and whether the VUR 
outcome is favourable with ET compared with continuous antibiotic 
prophylaxis (CAP) alone. Furthermore, to determine whether the 
development of bladder dysfunction during infancy can be prevented by 
early reflux resolution and whether early ET reduces the risk of UTI and 
renal scarring during follow-up. Lastly, we aimed to describe parents’ 
experiences of CAP, SI, UTI and renal damage. 
The first three papers present the results from the Swedish infant high-
grade reflux trial – an open, prospective, randomised, controlled, national 
multicentre study, in which we compared the outcomes (VUR resolution, 
bladder function, UTI recurrence and renal scarring) between the two 
treatment groups (ET vs. CAP). The study did not reveal any differences in 
bladder function, UTI recurrence or renal scarring between the two 
treatment groups, despite the superior effect of ET on VUR resolution and 
the fact that VUR-grade at follow-up correlated with both UTI recurrence 
and renal deterioration. Although bladder dysfunction could not be 
prevented by early VUR resolution, it can be seen as an important 
prognostic factor for VUR outcome. 
The fourth paper is based on focus group discussions, held with parents 
of children with infant hVUR, and describes the parents’ experiences of the 
treatment and outcomes. The focus group discussions revealed that both 
 CAP and the risk of UTI have a negative, everyday impact on family life, 
while renal damage appears to be less important to the parents. The 
concerns relating to SI are related to a single occasion, which can be 
optimised by proper care.  
VUR management should be individualised and risk adapted according 
to current knowledge and parents’ preferences should be considered. 
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 Sammanfattning på svenska 
Vid vesicoureteral reflux (VUR) har man ett patologiskt backflöde av urin 
från blåsan upp genom urinledaren till njurbäckenet. Barn med VUR löper 
större risk att få upprepade urinvägsinfektioner (UVI) och skador på 
njurarna. Bland spädbarn med medfödd höggradig reflux (hVUR) har 
majoriteten även en generell medfödd njurskada. Spädbarnen har dessutom 
ofta blåsdysfunktion som hos många innebär en onormalt stor blåsa med 
påverkad tömningsfunktion. VUR kan försvinna spontant med stigande 
ålder, men vid hVUR är denna chans relativt låg. Målet för all behandling 
av VUR är att förebygga nya infektioner och samtidigt minimera den 
morbiditet som är kopplad till utredning och behandling. Kirurgisk 
refluxbehandling – endoskopisk injektionsbehandling (ET) eller öppen 
operation – syftar till att skapa en kompetent vesicoureteral övergång och 
är indicerad vid genombrottsinfektioner eller om progredierande njurskada 
ses trots antibiotikaskydd. 
I delarbete I-III redovisas resultatet av Den Svenska Spädbarnsreflux-
studien, där man i en prospektiv, randomiserad, kontrollerad, 
multicenterstudie undersökt om antibiotikaprofylax eller ET är att föredra 
vid hVUR hos spädbarn avseende I) nedgradering av reflux, II) 
blåsfunktion och III) UVI och njurskada. Denna studie fann ingen skillnad 
i blåsfunktion, förekomst av UVI eller njurskada mellan de två 
behandlingsgrupperna trots större chans till refluxfrihet i ET-gruppen samt 
en korrelation mellan hög VUR-grad vid uppföljning, antal UVI-recidiv 
och njurskada. Blåsdysfunktion kunde inte förebyggas med tidig 
refluxfrihet, men kan ändå ses som en viktig prognostisk faktor avseende 
refluxutfall. 
I det fjärde delarbetet presenteras en kvalitativ studie där vi använde 
fokusgruppmetodik för att utforska föräldrars erfarenheter av hVUR hos 
spädbarn, avseende antibiotikabehandling, kirurgi/endoskopi, UVI och 
njurskador. Resultatet av fokusgrupperna visade att antibiotikaprofylax och 
risken för UVI verkar innebära en dagligt återkommande, icke-försumbar 
påverkan av familjelivet, medan njurskada verkar ha mindre betydelse ur 
föräldrars perspektiv. Erfarenheterna av kirurgi/endoskopi är relaterade till 
ett enstaka vårdtillfälle som kan optimeras med små medel och adekvata 
förberedelser. Föräldraperspektivet bör tas i beaktande vid handläggning av 
spädbarn med höggradig VUR.
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1. Introduction 
1.1 Definition 
Vesicoureteral reflux (VUR) is the retrograde backflow of urine from the urinary 
bladder into the ureter and towards the kidney, secondary to a dysfunctional 
vesicoureteral junction. A functional vesicoureteral junction is dependent on the 
length of the submucosal ureter, the width of the ureteral orifice, the muscles in 
the ureter and trigone of the bladder and co-ordinated ureteric peristalsis.  
VUR is associated with an increased risk of pyelonephritis and renal scarring, 
with potentially serious consequences such as hypertension and renal failure. 
The main goal in VUR management has therefore been the preservation of 
kidney function by minimising the risk of pyelonephritis. In this summarising 
chapter, we will discuss whether this approach is still valid and what we can 
learn from the last 40 years of research. 
 
 
 
 
 
 
 
Figure 1 The vesicoureteral junction. Modified from Harrison JH, et al, eds. Campbell’s 
Urology, 4th ed. Philadelphia: WB Saunders, 1979:1597, with permission from Elseiver   
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1.1.1 Grading 
VUR is visualised with cystography and graded by its severity, according to the 
International Reflux Study in Children standards [1]. The grading depends on the 
degree of filling and dilatation of the ureter and upper urinary tract, visualised by 
filling the bladder with contrast. Grades I-II are referred to as non-dilating VUR 
and grades III-V as dilating VUR. 
 
 
 
 
 
 
 
Figure 2 International grading system of VUR, from www.radipedia.com, with permission. 
1.1.2 Prevalence 
Studies reporting the frequency of VUR give inconsistent results. Much of the 
variation can be attributed to study design, particularly the differences in 
diagnosing VUR, selection bias, large age ranges and sampling bias. Possible 
confounders when analysing prevalence are the fact that the majority of VUR 
diagnoses are related to a history of urinary tract infections (UTIs) and that VUR 
is known to resolve spontaneously with age [2]. Studies of VUR prevalence in 
The international system for the radiographic grading of VUR 
Grade I Contrast in ureter only 
Grade II Contrast in ureter, pelvis and calyces; no dilatation of calyceal 
fornices 
Grade III Mild or moderate dilatation of the ureter and the renal pelvis. 
No or only slight blunting of the calyces. 
Grade IV Moderate dilatation and/or tortuosity of the ureter and moderate 
dilatation of the pelvis and calyces. Maintenance of the 
papillary impressions in the majority of calyces. 
Grade V Gross dilatation and tortuosity of the ureter and of the renal 
pelvis and calyces. The papillary impressions are no longer 
visible in the majority of calyces. 
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children evaluated for UTI have reported values between 25-40% [3, 4]. 
Calculating with a cumulative incidence of UTI in children of 5% [5], 
approximately 1.25-2% of all children will be diagnosed with VUR after a UTI. 
The stated prevalence of VUR among siblings or first-order relatives of VUR 
patients is 30-45% depending on age and the study method [6, 7]. In infants with 
antenatal hydronephrosis, the prevalence is calculated to be 16% [7]. 
The true prevalence of VUR in otherwise healthy children remains uncertain: 
1% is probably an underestimate, and 10% to 20% may be possible, suggesting 
that VUR is largely asymptomatic [2]. There is a higher prevalence of VUR in 
males than females during infancy (3:1), but, in children older than two years, 
the sex ratio has shifted.  
 
 
1.2 History 
The first descriptions of retrograde flow of 
urine from the bladder to the kidney were 
given by Claudius Galenos (130–200 AD), a 
Greek physician, writer and philosopher from 
Pergamon. He produced hundreds of works in 
which he marked the history of medicine for 
almost 1,300 years [8, 9].  
In the 15th century, Leonardo da Vinci 
postulated an anti-reflux mechanism to 
prevent urine from returning into the ureters 
[10]. However, it was not until the 1950’s that 
two British radiologists were able to 
demonstrate the association between post-
infectious renal scars and VUR [11].  
 
 
The first anti-reflux surgery was performed in 1952 by Hutch [12] and the first 
intravesical ureteral re-implantation in 1958, by Victor Politano and Wyland 
Leadbetter [13]. The extravesical ureteral re-implantation was described in 1961 
by Lich et al. [14] and simultaneously and independently, on the other side of the 
Atlantic, Professor Gregoir in Munich developed a very similar technique [15]. 
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Figure 3 The Lich re-implant technique. Lich et al. J Ky Med Assoc, 1961 
Ureteral re-implantation, with some modifications here and there, became the 
gold standard therapy for the treatment of VUR for almost 20 years.  
The success of the surgical approach was tempered in the mid-1970s, when 
Smellie and Edwards et al. demonstrated relatively high rates of the spontaneous 
resolution of reflux on low-dose continuous antibiotic prophylaxis (CAP) and 
that CAP lowered the risk of developing new renal scars in most cases [16, 17]. 
This idea had been presented some years earlier by O’Donnell et al. and 
Lenaghan, but at that point it had not gained full acknowledgement [18, 19]. All 
children with VUR were now placed on low-dose prophylactic antibiotics, and, 
if this failed, surgical correction was recommended. Already at that time, infants 
with hVUR were regarded as a certain high-risk patient group. Open surgical 
repair was regarded as technically challenging in the small infant bladder and 
other temporary solutions such as refluxing ureterostomy were therefore often 
preferred. Later observational studies by Yeung and Sjostrom reported 
spontaneous resolution in this group as well [20, 21].  
In the mid-1990s, endoscopic treatment (ET) became a safe and effective 
alternative in the treatment of VUR, especially in older children. The Swedish 
reflux trial in children was a prospective, randomised study that compared ET 
with CAP and surveillance in 203 children, aged one to three with VUR grades 
III-IV in 2000-2009 [22]. During the study period, two of the study’s initiators 
postulated that it could be the extra load of refluxing urine on the infant bladder 
that caused the development of lower urinary tract dysfunction (LUTD) in small 
children with hVUR. To investigate their theory, they designed a study where 
infants < 8 months with high-grade reflux were randomised to either ET or CAP, 
with the hypothesis that early treatment of VUR would prevent the development 
of LUTD with a large bladder capacity and poor emptying ability –  this was the 
Swedish infant high-grade reflux trial [23]. 
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1.3 Embryology 
On day 35 of human gestation, the formation of the ureter and kidney starts with 
the emergence of the ureteric bud (metanephric diverticulum) from the 
mesonephric (Wolffian) duct near the urogenital sinus.  
The ureteric bud grows towards the primitive kidney (metanephric 
mesenchyme) which evokes reciprocal signals that induce differentiation. The 
cranial end of the ureteric bud becomes the renal pelvis and the stalk of the bud 
becomes the ureter. The common nephric duct (the most posterior part of the 
mesonephric duct) then undergoes apoptosis which brings the ureters into 
contact with the urogenital sinus epithelium and, after extensive epithelial 
remodelling, to their final trigonal positions [24, 25] (Figures 4 and 5). 
 
Figure 4 Urinary tract development and structure.  
(a) Early development of the urinary tract (fifth week of gestation). The ureteric bud from the 
mesonephric (Wolffian) duct meets the metanephric mesenchyme. 
(b) Elongation of the ureter and formation of the kidney (metanephros).  
Rasouly HM et al. Wiley interdisciplinary reviews. Systems biology and medicine, 2013, with 
permission from Copyright Clearance Center. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 The common nephric duct is progressively absorbed into the urogenital sinus. By 
week 7 the ureter and mesonephric (Wolffian) duct have separate openings and rotation 
takes place.  
https://abdominalkey.com/developmental-anatomy-and-urogenital-abnormalities/ 
Common 
nephric 
duct 
Mesonephric 
duct 
Ureter 
 24   1 .  INTRODUCTION  
 
1.3.1 Clinical correlation 
The final position of the ureteral orifice depends on the position at which the 
ureteric bud evaginates from the mesonephric duct, which depends on the 
location and timing of the contact with the metanephric mesenchyme. For 
example, excessive caudal budding on the mesonephric duct will result in the 
poor development of a short intramural tunnel, an incompetent vesicoureteral 
junction and VUR. Concurrently, ureteral budding from an aberrant site contacts 
the metanephric mesenchyme at a point where mesenchymal cells are sparse and 
poorly differentiated, resulting in the development of hypo- and dysplastic 
kidneys [26]. 
1.4 Prognosis for VUR 
The outcome for most children with VUR is generally excellent. If the VUR 
prevalence were as high as 3 %, meaning that VUR occurs in 30,000 per million 
children, approximately 6,000 of them would be diagnosed with a UTI and only 
five per million children would develop end-stage renal disease [2]. Importantly 
however, the study population in this study has higher morbidity and a poorer 
prognosis than VUR children in general, which will be discussed further. 
1.4.1 Spontaneous resolution 
The spontaneous resolution or downgrading of VUR is dependent on the degree 
of reflux, age, sex and associated bladder dysfunction. Estrada et al. analysed the 
frequency of VUR resolution in 2,462 VUR patients. They found that VUR had 
a high spontaneous resolution rate during the first four to five years of life (60-
80% in grades I-II and 30-50% in III-IV) and that male sex, unilaterality and age 
< 1 year are positive predictors for resolution [27]. Similar results have been 
presented earlier: 39% downgrade in VUR grades III-V and a significantly 
higher resolution rate in males during infancy in VUR grades IV-V [21]; 35-45% 
resolution rate in grades III-IV after five years of follow-up [28] , 48% in grade 
IV after four years[29] and 51% in grades I-IV after two years [30]. 
The presence of bladder and bowel dysfunction (BBD) or lower urinary tract 
dysfunction (LUTD) is associated with a reduced probability of VUR resolution. 
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1.5 Infant high-grade VUR 
High-grade VUR (grades IV and V) diagnosed early in infancy represents a 
specific group of VUR children with special characteristics, which are most 
prominent in bilateral grade V. The latter often have pronounced dilatation of the 
upper urinary tracts and a large bladder. They are often boys, presenting with a 
febrile UTI, affected general condition and impaired renal function. This group 
runs a high risk of developing new renal scars from UTI, especially during 
infancy, and their risk of UTI is further increased by their high prevalence of 
bladder dysfunction with high bladder capacity and poor bladder emptying [20, 
31, 32]. To save renal function, it is sometimes necessary to treat these children 
temporarily with bladder drainage or a refluxing distal ureterostomy for a few 
months.  
Moreover, high-grade VUR is often associated with congenital renal 
abnormalities, such as hypo-dysplastic kidneys, and has a lower likelihood of 
spontaneous VUR resolution compared with lower reflux grades. In spite of this, 
there is a small group of children with high-grade VUR, but without the 
pronounced dilatation of the upper urinary tracts, where early VUR resolution 
can be seen, preferably during infancy [20, 21, 27].  
 
1.6 VUR-related morbidity 
1.6.1 LUTD/BBD 
Detecting non-neurogenic bladder dysfunction in children before toilet training 
is very different from after. After toilet training, the recommendation is to use a 
standardised bladder-bowel questionnaire with the registration of symptoms and 
preferably with the addition of flow/residual urine studies. In these studies, there 
is a clear co-prevalence of VUR and BBD, with some studies describing a BBD 
prevalence of 40-60% in toilet trained VUR children [33, 34].   
In non-toilet trained children, the registration of symptoms is not possible, 
explaining why non-neurogenic bladder dysfunction is difficult to recognise in 
infancy. In studies evaluating bladder function in infants with hVUR during the 
first year of life, characteristics of the urodynamic pattern is often similar to the 
voiding pattern demonstrated in healthy infants; a small to normal bladder 
capacity, a normal to high voiding pressure and with dyscoordinated voiding 
[35-38]. However, during the second year of life, it has been shown that the 
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urodynamic pattern changes to a high capacity bladder with increased post-void 
residual urine [37]. In contrast to these observations, one proportion of infants, 
preferable boys with bilateral VUR grade V mentioned in the previous section, 
seem to have a large BC already from the start. Whether it is the high volume 
load from the refluxing urine that affects the bladder and causes the abnormal 
increase in BC, noted in infants with hVUR, was one of the research questions in 
the present study [39]. 
According to the ICCS standardisation document, the term “lower urinary 
tract dysfunction (LUTD)” should be applied to symptoms from the urinary 
tract, whereas, if both urinary and bowel 
symptoms are present, the term should be 
“bladder bowel dysfunction (BBD)” [40]. 
LUTD, with or without bowel dysfunction, 
is associated with an increased risk of 
recurrent UTI, lower rates of VUR 
resolution and reduced success of surgical/ 
endoscopic treatment [41-43]. For this 
reason, early potty training should be 
encouraged and the management of VUR 
in toilet trained children should include 
treatment for bladder/bowel dysfunction, 
with an individualised selection of 
behavioural therapy, biofeedback, 
anticholinergic medications and 
constipation management [43].  
 
1.6.2 UTI 
VUR in itself does not cause UTI, but it does increase the risk of bacteriuria 
progressing to pyelonephritis. One of the pathogenic mechanisms is probably the 
endotoxin effects from bacteria which cause ureteral peristalsis to cease. This 
leads to an atonic ureter and a decreased rate of bacterial clearance from the 
upper urinary tract [44]. The same effect is seen in bilateral grade V with gross 
dilatation of the upper urinary tract, even without bacterial influence. UTIs are 
more common in girls than boys because of anatomic differences, but, among all 
the children with UTI, boys are more likely than girls to have VUR (29% vs 
14%) [45]. The only period when UTIs are more common in boys is during the 
first six months of life (Figure 6) [46].  
Figure 8 Large bladder capacity with 
bladder reaching above the iliac crest 
and bilateral high-grade VUR. 
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Figure 6 Age distribution of first known UTI in children aged 0-2 years, divided by sex.  
Minimum Incidence and Diagnostic Rate of First Urinary Tract Infection. Jakobsson et al. 
Pediatrics 1999, with permission from Copyright Clearance Center. 
 
1.6.3 Renal damage 
VUR is neither necessary nor sufficient for the development of pyelonephritis 
and renal scarring. Nevertheless, children with VUR are more likely to develop 
pyelonephritis and renal scarring compared with those with no VUR. Moreover, 
children with VUR grades III-V are more likely to develop renal scarring than 
children with lower reflux grades [43, 47]. A meta-analysis revealed that renal 
abnormalities occur in 6% of those with grades I-III and in 48% of those with 
VUR grades IV-V [7].  
Reflux nephropathy (RN) is renal scarring diagnosed in patients with VUR 
and can be either congenital (abnormal renal development) or acquired 
(pyelonephritis-induced renal injury). Renal dysplasia in VUR children is most 
probably due to poor nephrogenic differentiation very early in embryogenesis, 
rather than being caused by the back pressure effect of urine reflux on the 
developing foetal kidney, as previously suggested [26]. The differentiation 
between congenital and acquired RN can be challenging, especially when a renal 
scintigraphy before a pyelonephritis is missing. Congenital RN is almost 
exclusively seen in infant boys with bilateral VUR grade V [20].  
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1.7 Family screening for VUR  
Despite the increased prevalence of VUR in first-order relatives of VUR 
patients, the screening of family members is controversial. There are no 
randomised studies of the clinical outcome of screened versus non-screened 
children or siblings of reflux patients. Some authors believe that the early 
identification of children with VUR may prevent episodes of UTI, while others 
think that the screening of asymptomatic individuals may result in an 
overtreatment of clinically insignificant VUR. Both European and American 
guidelines recommend informing parents of the increased risk of VUR in 
siblings and offspring and, if screening is performed, the recommended modality 
is ultrasound. VCUG is performed if dilatation or renal scarring is detected on 
ultrasound or after a febrile UTI [43, 45].  
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1.8 Treatment of VUR 
1.8.1 Continuous antibiotic prophylaxis 
The purpose of continuous antibiotic prophylaxis is to keep the urine free from 
bacteria and thereby reduce the risk of retrograde renal infection. Since many of 
the reflux cases resolve with time, a conservative approach with CAP as the 
initial management option is often recommended [43, 45]. Nevertheless, the risk 
of UTI and acute pyelonephritis has to be weighed up against concerns about the 
possible side-effects of CAP and the emergence of multi-resistant strains of 
bacteria. 
Many well-constructed trials have been designed to determine the efficacy of 
CAP in preventing UTI with contradictory results and different conclusions. The 
International reflux study in children demonstrated an equal incidence of UTI in 
the two treatment arms (CAP or open surgery) and no difference in renal 
scarring [48]. The Swedish reflux trial reported significantly more UTI 
recurrences in girls than in boys, where the rate in girls was higher in the 
surveillance group compared with both CAP and endoscopy. Further, the rate of 
new renal damage in girls was higher in the surveillance group. There were no 
effects of CAP on UTI recurrence or renal damage in boys [49, 50].  
The PRIVENT study concluded that CAP had a limited effect on UTI 
recurrence [51]. The RIVUR trial enrolled 607 children with VUR grades I-IV 
after a UTI episode, randomised to CAP or placebo, and showed that CAP 
reduced the risk of UTI recurrences by 50% during the two-year follow-up [30]. 
According to a recent systematic review, CAP significantly reduced the risk of 
UTI in children with VUR, although it increased the risk of infection by 
antibiotic-resistant bacteria and CAP did not impact the occurrence of new renal 
scarring [52]. In spite of this, it can be concluded that, based on current 
evidence, CAP can be recommended in the first year of life, especially for 
children with dilating VUR who are not toilet trained and for patients with 
bladder bowel dysfunction [53].  
1.8.2 Surveillance 
Viewing VUR as a generally self-resolving condition makes active surveillance 
without prophylaxis an option in selected cases. A prerequisite for this approach 
is easy access to paediatric emergency care and parents being observant of any 
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sign of UTI, as the early use of antibiotics in the event of pyelonephritis 
significantly reduces the risk of renal scarring [54].  
1.8.3 Surgery 
Surgical intervention is an option in patients with persistent reflux, recurrent 
UTI, deterioration of renal function or parents’ preference to avoid CAP [43, 
45]. Surgical approaches are open ureteral re-implantation, endoscopic 
subureteric injection and robot-assisted laparoscopic ureteral re-implantation 
(RALUR). 
The goal of all surgery is to create a functional vesicoureteric junction.  
Open surgery 
Different intra- and extravesical open surgical procedures have been described. 
Creating an adequate length of the intramural tunnel is common in all methods. 
The Lich-Gregoir extravesical anti-reflux technique, Cohen intravesical re-
implantation and Politano-Leadbetter combined intra- and extravesical re-
implantation techniques are the most widely used methods. Open surgical repair 
has an excellent success rate (>95%) in experienced hands and older children 
[55], but it is regarded as technically demanding in the small infant bladder and 
involves in-patient hospitalisation and significant post-operative morbidity. 
 
 
 
 
Figure 7 Cohen intravesical re-implantation where the ureter is inserted into a submucous 
tunnel. Retik et al. Pediatric Urology. In: Paulson DF, editor. Genitourinary surgery, vol 2. 
New York: Churchill Livingstone, 1984, p. 764. 
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Endoscopic injection 
Endoscopic injection with a bulking agent in the submucosal intramural tunnel 
was introduced in the mid-1990s and it is now a minimally invasive alternative 
to both CAP and ureteral re-implantation in selected cases. 
Many bulking agents have been tested; a polyacrylate polyalcohol copolymer 
(Vantris®) and dextranomer-hyaluronic acid (Deflux®) are the most commonly 
used. The rate of reflux resolution has been demonstrated to correlate with the 
degree of VUR (80-90% in grades I-II, 60-70% in grades III-IV and 50-60% in 
grade V) and with lower success rates for duplicated compared with single 
systems [56, 57].  
Another factor that has a great impact on success rates is the length of follow-
up. Some studies have reported a high (>90%) success rate after four to six 
weeks [58], while studies with a longer follow-up suggest that the effect may not 
be lasting [59-61]. It can nonetheless be argued that even a temporary effect of 
ET can buy the child time for the reflux to resolve, or until it is less prone to 
recurrent UTIs and more suitable for open surgery [62, 63]. Compared with 
ureteral re-implantation, endoscopic injection is performed as an outpatient 
procedure with minimal post-operative morbidity. 
Robot-assisted laparoscopic ureteral re-implantation (RALUR) 
RALUR was introduced in 2004 and, today, the success rates of laparoscopic 
and robot-assisted anti-reflux surgery are comparable with those of open surgical 
techniques according to recent studies. Improved visualisation, ergonomic 
comfort for the surgeon, a shorter hospital stay and decreasing post-operative 
pain are some of the benefits. However, robot-assisted surgery has major 
disadvantages of longer operating times and higher costs [53, 64]. 
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1.10 VUR and quality of life 
“Health is a state of complete physical, mental and social well-being and 
not merely the absence of disease or infirmity.” 
From the Constitution of the World Health Organisation 1946 [65] 
 
In the evaluation of health care, clinical outcome is one component to consider. 
The other is the care-taker’s perceptions of health-related quality of life 
(HRQoL), which in this study applies to the way the different options of VUR 
management affect the HRQoL of the patient and parent. Based on the chronicity 
of the therapy and management of VUR, a potential impact on HRQoL can be 
anticipated, but the literature on HRQoL in paediatric VUR is still sparse. 
Previous studies have reported diverse and somewhat contradictory results, both 
regarding the families’ HRQoL [66-68] as well as the parents’ satisfaction and 
preferences [69-73].  
The lack of consistency in previous studies can be partly explained by the 
large-scale diversity in study populations. Many studies have mixed age-groups 
and all grades of VUR, which makes it difficult to draw any sharp conclusions.  
In the fourth paper in this thesis, we therefore chose to focus on a certain age-
group and grade of VUR, namely patients with VUR grades IV-V who were 
diagnosed before the age of six months. We wanted to find out how the parents 
had experienced the first two years of their child’s life. 
1.11  Introduction to qualitative  
research methodology 
 
“Not everything that counts can be counted and not everything that can be 
counted counts.”   
From a sign hanging in Albert Einstein’s office at Princeton, crediting Cameron, 1963. [74] 
 
Qualitative research seeks to answer questions about experience, meaning and 
perspective from the standpoint of the participant. Acquiring a rich and complex 
understanding of a specific social context or phenomenon is central in qualitative 
research, rather than obtaining data that can be generalised to other areas or 
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populations. In this way, qualitative research differs from quantitative research. 
If a quantitative approach aims to quantify variations and predict causal 
relationships, a qualitative approach describes variations and explains 
relationships. Where the quantitative approach seeks to confirm an hypothesis 
about phenomena, the qualitative approach seeks to explore the phenomena.  
With quantitative methods such as questionnaires, the responses are often 
fixed alternatives, pre-determined by the researcher. This requires a thorough 
understanding of the best questions to ask, how to ask them and the range of 
possible responses, but it also allows for comparisons of responses across 
participants. Instead, by using open-ended questions in interviews or group 
discussions, the participants are given the opportunity to respond in their own 
words and create responses that are rich and explanatory and sometimes 
unanticipated by the researcher [75]. 
1.11.1 Patient-centred outcomes research  
Patient-centred care is defined as “Health care that is compassionate, empathetic, 
and focused on the patient’s own worldview, goals, preference, values and 
needs” [76]. Patient-centred outcomes research makes it easier for patients and 
their caregivers to make informed health care decisions and helps the patient to 
assess the value of health care options. This research can be used to increase the 
quality of healthcare and push the healthcare system towards a more patient-
centred approach [76-78].  
When investigating patients’ subjective experiences of health and received care, 
patient-reported outcomes (PRO) and patient-reported experiences (PRE) are 
commonly studied.  
In PRO, the report of outcome comes directly from the patient, without any 
interpretation of the responses by a clinician or anyone else. It includes different 
health parameters, such as signs, symptoms, functional capacity and health-
related quality of life (HRQoL). Patient-reported outcome measures (PROMs) 
are tools that aim to measure the outcomes, such as indices and questionnaires.  
PRE covers aspects of the structure and processes of care, as experienced by 
the patient. It includes respect for patients’ values; information and 
communication; involvement of family; emotional support; continuity; access to 
care; and cleanliness of the environment. PREMs measure the patients’ 
experiences of the given care and are distinct from measurements of satisfaction, 
as the latter are strongly affected by both expectations and outcomes [79, 80].  
When assessing the health status of younger children, it is common to only 
assess the perspective of parents as observers or proxies of the children’s 
 34   1 .  INTRODUCTION  
 
treatment and health outcomes [81]. The family can be considered the child’s 
primary source of strength and support to health and development [82]. In the 
present study (Paper IV), the intention was therefore to assess the family impact 
of infant hVUR from the parents’ perspectives.  
1.11.2 Evaluating qualitative research 
Some quantitatively trained researchers view qualitative research with suspicion 
and regard it as unserious, because it involves small samples which may not be 
representative of a broader population. Qualitative research can also be criticised 
for being subjective in the sense that the results may be influenced by the 
researchers own experiences and opinions. The common knowledge of what 
constitutes rigour or quality in qualitative research is therefore limited [83]. 
A qualitative study has the same requirement for procedural description as a 
quantitative study. The purpose of the study, how it was conducted, including 
the details of data generation and management, should be transparent and 
specific. A reviewer should be able to follow the chain of events and understand 
the logic of the decisions and choices of methodology and methods [84].  
In qualitative research, the concepts credibility, dependability and 
transferability of the study are often used to describe various aspects of 
trustworthiness [85], representing a quality control. In qualitative research, 
saturation and variation are discussed instead of significances and p-values. All 
these concepts are as strict and specific as the ones in quantitative research, and 
this needs to be fully understood when evaluating the quality of a qualitative 
study.  
1.11.3 Methods of data collection 
Examples of methods of data collection include in-depth interviews, 
observations, fieldwork, focus groups and the study of events, videos, art or texts 
like diaries, blogs and books, among many others. The choice of method 
depends on the research question, study population and the time and resources of 
the project. In this study, we chose focus group discussions as the method of data 
collection. 
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Focus group research 
Focus groups can be described as “a carefully planned discussion designed to 
obtain perceptions on a defined area of interest in a permissive, non-threatening 
environment” [86]. The primary aim of a focus group is to acquire an 
understanding of a specific issue from the perspective of a selected group of 
people. Ultimately, focus group discussions encourage a wide range of responses 
which provide the researcher with different attitudes, behaviour, opinions and 
perceptions of the participants [87]. 
“The goal of the group is to elicit a discussion that allows the researcher 
to see the world from the participants’ perspectives.”  
Heary et al. 2012 [88] 
Researchers have used focus groups for the past 90 years. In the 1920s, they 
were used to assist researchers in identifying survey questions. Later, focus 
group data were collected and analysed mainly to assess consumer attitudes 
and opinions in marketing research. In the past 20 years, social science 
researchers have used focus groups to collect qualitative data in an 
economical, fast and efficient manner [89]. 
A focus group usually lasts between one and two hours and consists of three 
or more participants. The number of participants should be sufficient to yield 
diversity in the provided information, but too large a group can cause 
participants to feel uncomfortable about sharing their thoughts and experiences 
[89]. The use of very small focus groups, “mini-focus groups”, with three or four 
participants, can be used when the participants have specialised knowledge or 
experiences to discuss within the group [86]. 
 
“For many novice researchers, analysing qualitative data is found to be 
unexpectedly challenging and time-consuming.”  
Erlingsson and Brysiewicz. 2017 [90] 
1.11.4 Methods of data analysis 
There are numerous different methods/approaches to analysing qualitative 
research. Each one has a different theoretical scientific foundation, area of 
application and specific traits. For example, phenomenology is grounded in 
scientific philosophy and focuses on the perceived world (“lifeworld”), 
hermeneutics focus on language and the interpretation of a “hidden meaning”, 
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ethnography is often used in field work to understand the other’s perspective 
“from the inside” and phenomenography has its roots in pedagogics and 
emphasises variations – “all voices should be heard”. Grounded theory is a 
research approach which follows its own very specific set of rules. Data 
collection (often through individual interviews) and analysis proceed 
simultaneously and streamline one another.  In this study, we chose to use 
content analysis. 
 
 “Regardless of the ‘quality’ of qualitative data, its sheer quantity can be 
daunting, if not overwhelming. Hundreds of pages of data can lead the 
researcher to think that it cannot be managed.”  
Elo & Kyngäs. 2007 [91] 
Qualitative content analysis (QCA) 
In contrast to other qualitative research methods, content analysis is not linked to 
any particular science, which explains why there are fewer rules to follow and 
the risk of confusion in matters relating to philosophical concepts and 
discussions is thereby reduced [92]. CA can be used both quantitatively and 
qualitatively, where the quantitative approach derives from logistic positivism 
and the qualitative approach from hermeneutics. This makes it possible to work 
with QCA in many different ways. 
In 1952, Berelson defined content analysis as “a research technique for the 
objective, systematic and quantitative description of the manifest content of 
communication”. He introduced quantitative content analysis, in which facts 
from the text are presented in the form of frequency expressed as a percentage or 
actual numbers of key categories [93].  
In this study, we chose to use manifest content analysis, in which the 
researcher describes what informants say, as close to their own words as 
possible, representing the visible and obvious in the text. Another form of 
content analysis is latent analysis, where the researcher seeks to find the 
underlying meaning of the text, on an interpretive level [92].  
In the process of QCA, the text is divided into meaning units. A meaning unit 
is the constellation of words or statements that relate to the same central 
meaning. The meaning units are then condensed, a process of shortening while 
preserving the core. In the abstraction phase, the condensed meaning units are 
labelled with a code. Labelling a condensed meaning unit with a code allows the 
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data to be thought about in new and different ways and should be understood in 
relation to the context. Finally, the codes are sorted into categories [94].  
According to Graneheim and Lundman, the creation of categories is the core 
feature of qualitative content analysis. [94]. No data should be excluded due to 
the lack of a suitable category and no data should fit into more than one 
category. A category answers the question ‘What?’ [95] and can be seen as a 
thread throughout the codes. A category refers to the descriptive level of content 
and is thereby an expression of the manifest content of the text [90].  
 
 
 
 
 
 
 
 
 
Erlingsson et al. 2017 
“Experiencing chaos 
during analysis is 
normal.” 
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2. Aims 
This research project is an attempt to shed some light on the management of 
infants with vesicoureteral reflux (VUR) grades IV-V. The objective was to 
evaluate different treatment options for high-grade VUR and to compare the 
results regarding VUR outcome, bladder function, urinary tract infections and 
renal damage. Furthermore, we wanted to add the parents’ perspective on VUR 
management, since the patient’s experience is central when measuring treatment 
success and quality of care. 
 
Papers I-III present the results from the Swedish infant high-grade reflux trial, 
which aimed to: 
 determine whether high-grade VUR in infants can be treated 
endoscopically and whether endoscopic injection is superior to 
antibiotic prophylaxis in the treatment of VUR 
 determine whether the early down-grading of reflux can prevent the 
development of bladder dysfunction with high bladder capacity and 
poor emptying ability 
 investigate whether successful endoscopic treatment can reduce the risk 
of UTI recurrence and renal scarring 
 
Paper IV presents selected results from a focus group study with parents of 
children with infant high-grade VUR, in which we aimed to: 
 describe the parents’ experiences of different treatment options 
(antibiotic prophylaxis and surgical intervention), recurrent UTI and the 
risk of renal damage 
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3. Patients and Methods  
3.1 Papers I-III 
 
3.1.1 Study design 
In this randomised, prospective, controlled 
multicentre trial, infants aged < 8 months, 
with VUR grades IV-V, were included 
between 2004 and 2014. A total of 21 
referral paediatric centres from different 
Swedish regions participated. If parents 
accepted participation, renal scintigraphy 
and GFR assessment were performed. If no 
exclusion criteria were met, bladder function 
was assessed and the child was randomised 
to either ET (with CAP until resolution) or to 
CAP alone.  
The exclusion criteria were renal function 
of < 40% of expected, a split function of < 
15% in the refluxing kidney, vesicoureteral 
obstruction, other urological malformation 
(except duplication), neurogenic bladder 
dysfunction or suspected parental non-
compliance.  
 
 
The randomisation process was computerised to match for sex, presentation, 
grade of VUR, DMSA abnormalities, bladder size, duplicated system and 
referral centre.  
The result of the ET was evaluated with VCUG and ultrasound two months 
after injection. Follow-up in both treatment groups was scheduled at two, six, 
nine and 12 months. Weight, height and blood pressure were recorded on all 
Referral paediatric centres 
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visits and antibiotic consumption since the previous contact was registered. 
Information regarding any breakthrough UTI and possible side effects of 
treatment was thoroughly analysed and urine cultures were re-examined.  
At one year after inclusion, all the study subjects were examined according to 
study protocol. VUR-grades 0-II at follow-up were regarded as a successful 
VUR outcome, since no treatment other than surveillance or CAP is 
recommended for these infants in international guidelines [1]. 
The primary outcomes in Studies I-III were reflux status, signs of bladder 
dysfunction, recurrent UTI and a deterioration in renal damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Study design 
3.1.2 Participants 
Seventy-seven infants (55 boys) were included, in whom VUR was diagnosed in 
the work-up after febrile UTI (n=55), after findings of hydronephrosis on 
prenatal ultrasound (n=21) or because of heredity (n=1). The median age at 
presentation was 1.6 months (SD 1.79, range 0-7 months) and the median age at 
inclusion was 6.7 months. VUR grade IV was seen in 30 and grade V in 47 
patients. 52 (68%) had bilateral reflux (18 grade IV and 34 grade V), 39 infants 
were randomised to CAP and 38 to ET. The baseline characteristics are listed in 
Table 1. 
 
 
2 months after ET 
Inclusion 
 
n=77 
 
VCUG, ultrasound  
DMSA/MAG3  
Clearance  
Bladder function 
One-year 
follow-up 
 
VCUG 
DMSA/MAG3 
Clearance  
Bladder 
function 
 
 
VCUG + ultrasound 
x 1
Clinical visits 
2, 6, 9 months 
Study start January 2004         Last patient included June 2013          Last follow-up July 2014 
ET 
n=38 
CAP 
n=39 
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Variable 
Total 
(n=77) 
Endoscopic 
treatment 
(n=38) 
Prophylaxis 
(n=39) p-value 
Sex     
Girls 22 (29%) 12 (32%) 10 (26%)  
Boys  55 (71%) 26 (68%) 29 (74%) 0.75 
Age at presentation 
(months)  
1.6 (1.8) 
1.3 (0.0; 6.6) 
1.7 (1.8) 
1.1 (0.0; 5.6) 
1.6 (1.8) 
1.4 (0.0; 6.6) 
0.82 
Age at randomisation 
(months) 
6.7 (1.2) 
7.0 (4.1; 9.2) 
6.8 (1.2) 
7.2 (4.1; 9.2) 
6.7 (1.1) 
6.9 (4.7; 8.8) 
0.65 
Presentation     
- UTI 55 (71%) 28 (74%) 27 (69%) 0.86 
- Antenatal 
dilatation 
21 (27%) 10 (26%) 11 (28%) 1.00 
- Heredity 1 (1%) 0 (0%) 1 (3%) 1.00 
Grade of VUR at baseline     
IV            30 (39%) 15 (40%) 15 (39%)  
V            47 (61%) 23 (61%) 24 (62%) 1.00 
Bilateral VUR 52 (68%) 25 (69%) 27 (69%) 0.94 
Duplex 12 (16%) 8 (21%) 4 (11%) 0.35 
Renal damage baseline     
No            10 (13%) 6 (16%) 4 (10%)  
Yes          67 (87%) 32 (84%) 35 (90%) 0.70 
Bladder capacity at 
baseline (normal/large) 
    
< 150%  42 (58%) 19 (53%) 23 (64%)  
≥ 150% 30 (42%) 17 (47%) 13 (36%) 0.47 
Residual volume at baseline 
(normal/large) 
    
< 20 ml  54 (75%) 24 (67%) 30 (83%)  
≥ 20 ml 18 (25%) 12 (33%) 6 (17%) 0.17 
 
Table 1 Baseline characteristics 
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Drop-outs 
The number of infants assessed for eligibility and their reasons for exclusion 
have not been registered. Information on the 77 included study subjects is given 
in detail in the Consort flow diagram, included in the Appendices and presented 
in Paper I [23].  In short, none of the included patients was lost to follow-up and 
all the patients but one in each treatment group could be analysed according to 
the ITT principle. 
3.1.3 Imaging  
VCUG 
Voiding cystourethrography remains the gold 
standard for grading VUR and assessing 
bladder configuration, despite its invasive 
nature and concerns about ionising radiation. 
The average radiation dose for a VCUG in a 
patient aged 0-2 years is 0.1-0.4 mSv in a 
standard paediatric radiology setting. The use 
of VCUG is nowadays often postponed until 
after evaluation with ultrasound and/or renal 
scintigraphy in the follow-up after febrile UTI 
or antenatal hydronephrosis.  
In this study, VUR was diagnosed by VCUG and graded according to the 
International Reflux Study in Children [1]. The highest VUR grade was used to 
classify each patient with bilateral VUR or duplex.  
Urinary tract ultrasound 
Ultrasound (US) is the most widely available, inexpensive and radiation-free 
means of obtaining anatomical information about the urinary tract. It is limited, 
as it is operator dependent and unable to provide a quantitative assessment of 
relative function and may not detect all renal scarring. In spite of this, it is 
recommended as the first standard evaluation for children with antenatal 
hydronephrosis and after an initial febrile UTI. VUR is rare in infants who have 
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two consecutive normal postnatal US and, if present, it is almost always low-
grade [96, 97].  
In this study, a US was performed to evaluate hydronephrosis and to exclude 
other urogenital abnormalities. 
All radiological investigations were re-evaluated at the co-ordination centre by 
a single paediatric radiologist according to a study protocol. 
3.1.4 Assessment of renal function 
Renal imaging: MAG3 & DMSA 
Renal scintigraphy provides information regarding the degree of renal cortical 
abnormalities. The limitations include the expense, radiation exposure, possible 
need for sedation and limited availability. The average radiation dose for one 
DMSA is approximately 1 mSv and, for MAG3, 0.5 mSv [98]. Internationally, 
renal scintigraphy is often used in VUR evaluations if VCUG has revealed a 
reflux. In contrast, both the ESPR (European Society of Paediatric Radiology), 
the Swedish Paediatric Society and the AAP’s revised guidelines endorse a 
fundamentally different post-UTI recommendation that focuses on kidney 
involvement. It is known as the top-down approach and begins with a US and 
DMSA renal scan. VCUG should be only performed for recurrent UTI or if renal 
involvement is identified, based on the belief that no child with a normal initial 
scan has a clinically significant reflux [99-101].  The benefits would be reduced 
urethral catheterisations, decreased ionising radiation to the gonads and reduced 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Example of two DMSA scintigraphies from the study. 
1a. Generalised damage in the right kidney with separate function 71% sin, 29% dx 
1b. Focal damage in the left kidney (arrow) with separate function 42% sin, 58% dx 
1a 1b 
Dx 
Dx 
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detection of “clinically insignificant” VUR [102-104].  
In this study, 99mTc-DMSA was the first method of choice for renal 
parenchymal imaging, but 99mTc-MAG3 scintigraphy was used to rule out 
ureteric obstruction (if poor drainage of the reflux on VCUG and dilatation on 
US) or depending on local preferences. The renal damage was characterised as 
focal, multifocal or generalised. New renal damage was defined as an uptake 
defect in previously normal parenchyma and the progress of damage was 
defined as a reduction in split renal function of ≥4 percentage points in a kidney 
with a pre-existing parenchymal defect [105]. Renal deterioration encompasses 
both new renal damage and the progress of renal damage. 
Clearance 
The glomerular filtration rate (GFR) is low at birth, but it increases rapidly 
during the first months of life. The filtration, related to body surface, increases 
between 0-2 years of age and then remains stable, with a reference value of 110 
ml/min/1.73m2. 
The GFR in this study was assessed with 51Cr-EDTA or Iohexol clearance or, 
when missing, formula clearance was estimated according to the Schwartz 
formula: 
 eGFR(ml/min per 1.73m2) = 36.5 x (length(cm) / S-creatinine(μmol/l)) [106]  
Age-adjusted reference values for filtration rate between 0-2 years of age were 
calculated using Winberg’s algorithm (log y = 0.209 x log(age in days) +1.45) 
[107] and a filtration rate of < 80% (< 2SD) of expected for age was considered 
subnormal.  
The renal function investigations were performed in accordance with European 
procedure guidelines [108, 109] and were reviewed by a single paediatric 
nuclear medicine specialist at the co-ordination centre.   
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3.1.5 Assessment of bladder function 
Free voiding observation (FVO) 
VUR and abnormal bladder function are 
associated with one another and with 
UTI. VUR outcomes are affected by the 
presence or absence of bladder 
dysfunction as mentioned earlier in 
Section 1.6.1. 
In this study, bladder function was evaluated 
with free voiding observations (FVO), in which the number of voids, voided 
volume and post-void residual urine (PVR) were registered during a period of 
four hours [110]. Voided volume was assessed by weighing the diaper and PVR 
measured with ultrasound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Four-hour free voiding observation 
 
 
The mean residual during four hours was noted as the PVR value and bladder 
capacity (BC) was estimated as the largest sum of voided and residual volume 
according to earlier studies of healthy children and the international 
standardisation document [40, 111]. Abnormal values for BC were ≥ 150 % of 
expected for age, calculated using the formula (30 + 2.5 x age in months) ml and 
for PVR ≥ 20 ml. Lower urinary tract dysfunction (LUTD) was defined as BC ≥ 
150 % of expected in combination with PVR ≥ 20 ml. 
VUR Bladder dysfunction 
Recurrent UTI 
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Videocystometry (VCM) 
Urodynamic studies investigate the filling and emptying phases of bladder 
function and are not routinely used to evaluate bladder function in neurologically 
intact children. A VCM can be explained as a filling and voiding cystometry 
with a simultaneous VCUG [37]. 
In this study, VCM was only available at the study centre and was therefore 
only performed in fewer than a third of the study subjects. The VCM studies 
gave us information on true post-void residuals and the volume of refluxing 
urine in those children.  
 
 
 
Figure 4. Concept sketch of a cystometry setting. Intravesical and abdominal pressure are 
measured using one probe in the bladder and one probe in the rectum. In addition, 
electromyography (EMG) is used to evaluate the activity of the muscles of the pelvic floor. 
Modified from Aoki, Y. et al. (2017) Urinary incontinence in women. Nat. Rev. Dis. Primers. 
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3.1.6 Treatment of VUR according to study protocol 
Continuous antibiotic prophylaxis (CAP) 
All the children were prescribed antibiotic prophylaxis when VUR was 
diagnosed. The choice of agent was left to the treating paediatrician to decide, 
but in most cases trimethoprim was used (0.5 to 1 mg/kg once daily), as a single 
drug or combined with sulfamethoxazole. Optional agents were 1 mg/kg of 
nitrofurantoin, 5 mg/kg of cefadroxil and 1 mg/kg of ciprofloxacin. 
Endoscopically treated patients received antibiotic prophylaxis until VUR grades 
0-II was observed.  
Endoscopic treatment (ET) 
ET was performed under general anaesthesia as an outpatient procedure at four 
paediatric surgical centres.  Dextranomer/hyaluronic acid copolymer (Dx/HA) 
was used as a bulking agent and injected submucosally, according to the 
standard technique [112]. 
 
Figure 5 Endoscopic injection technique. Courtesy of Stephan Spitzer, www.medizillu.de 
Patients in the ET group had VUR re-graded and dilatation evaluated two 
months after the first injection. If VUR grade > II persisted, a second injection 
was performed. 
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3.1.7 Febrile UTI – definition  
In children presenting with fever of > 38°C, the diagnosis of febrile UTI was 
based on a positive dipstick for leucocyte esterase or nitrite in combination with 
a significant bacterial count of a pure colony. A significant count refers to ≥ 105 
CFU/ml in the clean catch/bag specimen, ≥ 104 CFU/ml in a catheter or any 
growth in bladder aspiration [113]. 
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3.2 Paper IV – the focus group study 
3.2.1 Study design  
This study was designed according to well-established methodology and 
international guidelines [114]. Following a thorough literature review, the 
authors constructed a VUR-specific focus group manual with nine semi-
structured and open questions, included in Appendices. We planned for four 
focus group discussions with approximately five participants in each group, 
stratified for treatment, sex and pre/postnatal diagnosis of the child. The criteria 
for the selection of study participants and the sample size were based on 
recommendations for qualitative studies of this nature [89].  
3.2.2 Participants 
The inclusion criteria were children born in 2012-2016 with VUR grades IV-V, 
diagnosed at < 6 months of age and treated at our clinic. The exclusion criteria 
were renal function < 40% of expected, neurogenic bladder dysfunction, other 
urogenital anomaly or surgery on the urinary tract, language difficulties and 
other morbidity that may affect the outcome of QoL and family impact. We 
identified 82 children, of which 43 were eligible after the exclusion of 39. After 
stratification, randomisation, invitation and some cancellations, we performed 
four focus groups with 19 parents (13 mothers) of 15 children (Figure 6). 
3.2.3 Data collection 
Four standardised focus groups were held outside the hospital environment and 
all the participants were asked identical questions according to the focus group 
manual. The discussions were led and facilitated by a trained moderator 
(MDB=1, JN=3) who ensured that the discussions were kept on track, that all the 
participants were given the opportunity to take part and that no one dominated 
the discussion. The discussions were recorded digitally and a research assistant 
(MDB=3, JN=1) was responsible for making field notes of non-verbal 
communication and group interactions.  
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82 
VUR, born 2012-2016
43 eligible
16 CAP a
5 parents in 
focus group 1
Focus group 1
2 fathers & 3 mothers               
to 2 girl/2 boys
5 parents in 
focus group 2
Focus group 2
1 fathers & 3 mothers               
to 1 girl/3 boys
27 SI b
5 parents in 
focus group 3
Focus group 3
2 fathers & 3 mothers               
to 1 girl/2 boys
5 parents in 
focus group 4
Focus group 4 
1 father & 4 mothers              
to 2 girls/2 boys
39 excluded c
Figure 6 Flow chart of the inclusion/exclusion/randomisation process. 
a 16 patients treated with CAP alone 
b 27 patients treated with CAP and SI (endoscopic treatment, ureteric reimplantation and hemi-nephrectomy) 
c Reason for exclusion: VUR grades I-III (n=25) 
Other urogenital anomaly or renal disease (n=7) 
  Earlier surgery on the urinary tract (n=3) 
  Non-Swedish speaking (n=2) 
  ESRD (n=1) 
  Wrong diagnosis (n=1) 
STRATIFICATION & RANDOMISATION 
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3.2.4 Data analysis 
The recorded material was transcribed into text verbatim and used for content 
analysis. The text analysis was performed using NVivo 11 Pro©, a software 
program that is useful when sorting and categorising a large amount of data. All 
experiences were extracted from the transcripts, divided into meaning units and 
condensed into statements. The statements were then categorised through a 
reflective, back-and-forward sorting process by two researchers (JN, MDB). 
 
 
 
Table 2 Examples of the process of text analysis, from raw data to results. 
 
 
 
 
 
 
 
Meaning unit Condensed 
MU 
Code Sub-category Category Heading 
And then it’s 
hard to say: 
”No, you 
can’t be here, 
’cause you’ve 
got a cold” – 
it feels so 
damn stupid. 
Hard asking 
someone to 
leave 
because 
he/she has a 
cold. 
Avoid 
seeing 
people with 
infections 
due to the 
child’s risk 
of being 
infected. 
Restricted 
social family 
activities due 
to ongoing 
UTI or fear 
of other 
infection 
Family 
impact 
due to the 
child’s 
UTI 
UTI 
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3.3 Statistical analysis 
3.3.1 Papers I-III 
Statistical analyses were performed according to a statistical analysis plan, 
developed by statistical consults in collaboration with the research team. For 
tests between two groups, Fisher’s exact test was used for dichotomous 
variables. The Mantel-Haenszel chi-square test was used for ordered categorical 
variables, and the chi-square test for non-ordered categorical variables.  
For continuous variables, Spearman’s rank correlation coefficient was used 
between two variables within a group and the Mann-Whitney U-test was used 
between groups. 
In Paper II, for change over time within a group, the sign test was performed 
with respect to categorical variables, while Wilcoxon’s signed-rank test was used 
for continuous variables.  
For probabilities, logistic regression was used. In Papers I and II, the best 
multivariable model was obtained by using stepwise logistic regression. From 
these analyses, the odds ratio (OR), 95% confidence intervals (CI), p-value and 
area under receiver operating curve (ROC) were given. OR is the ratio for the 
odds of an increase in the predictor of one unit. 
All tests were two-tailed and conducted at the 0.05 significance level and all 
analyses were performed using SAS version 9.4 (SAS Institute Inc. Cary, NC, 
USA). 
The results were analysed and presented according to allocated treatment 
using the intention-to-treat (ITT) principle, unless otherwise stated. 
According to power analysis calculation, a sample size of 68 patients would 
be needed to detect a difference between the two groups with 80 % power 
regarding the reflux cure rate and bladder function. The power-calculated 
number of participants was reached. 
3.3.2 Paper IV 
Descriptive statistical analysis of the data was performed, and the frequency (%) 
and distribution of statements according to UTI/renal damage, SI and CAP 
categories in total/CAP/SI groups were performed using Microsoft Excel 2010.  
According to focus group methodology, a larger number of statements within 
a category indicate greater relevance to the participants. However, p-values are 
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not applicable in focus group methodology and, as recommended, statistical 
hypothesis testing was therefore not performed [89].  
3.4 Ethical considerations 
 
There are three fundamental research ethics principles, originally published in 
The Belmont Report [115]. The first is respect for persons, meaning respecting 
all research participants’ dignity and autonomy and protecting them from 
exploitation and vulnerability. Beneficence is the second, which commits the 
researcher to articulating how he/she plans to minimise the risks associated with 
research (also psychological and social) and maximise the benefits. The third is 
justice, which means ensuring a fair distribution of the risks and benefits 
resulting from research, i.e. those who are expected to benefit from the 
knowledge should be the ones who are asked to participate. 
 
 
The Swedish infant high-grade reflux trial was approved by the regional ethics 
committee as early as 2003 (Ö 140-03) and also by local ethics committees at 
every participating centre. The original research question regarded endoscopic 
treatment of VUR grade V in infants and whether early reflux resolution could 
prevent the development of bladder dysfunction. The estimated number of 68 
patients was calculated, based on the hypothesised difference between the groups 
in terms of VUR outcome and bladder dysfunction with 80% statistical power. 
Later, the decision to include patients with VUR grade IV was added to the 
study. This addition to the research project did not necessitate any ethical 
considerations. Since the participating surgeons were familiar with ET in older 
children, no technical issues with the procedure in infants was expected. The 
advantage of offering a possible cure for the condition outweighed the risks 
associated with the intervention.  
 
 
The focus group study was approved by the Regional Ethical Review Board in 
Gothenburg, Sweden (Dnr 1095-17), and complies with the principles outlined 
in the World Medical Association Declaration of Helsinki 2009.  
When using focus groups, it is important to consider that disclosures by 
participants are shared not only with the researchers, but also with the rest of the 
group. Focus group discussions can also create distress in some individuals, 
which has to be dealt with. We considered the research topic in this study as of a 
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less sensitive nature, but efforts were still made to minimise stress and 
discomfort for the participants. 
 
In both the Infant high-grade reflux trial and the Focus group study, the 
participants received written information about the research study, which was 
followed-up by a phone call. They were informed that participation was 
voluntary and that they could withdraw at any time. An informed consent was 
obtained from each participating family. The identity and integrity of the 
participants were, and still are, protected at all times and their confidentiality is 
assured.  
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4. Results 
4.1 Results papers I-III 
4.1.1 VUR outcome 
In both treatment groups, the reflux status improved during follow-up. Down-
grading to VUR grade ≤ II was seen in 30 patients, 22 (59%) in the ET group 
and eight (21%) in the CAP group (p=0.0014) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 VUR status at the one-year follow-up according to ITT. Green indicates VUR 
grade ≤ II and blue indicates VUR grades III-V. 
 
 
41%
79%
13%
5%
46%
16%
0%
25%
50%
75%
100%
Endoscopic treatment Prophylaxis
No VUR
VUR I-II
VUR III-V
p=0.0014
59%
21%
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The rate of down-grading in the ET group was 100% in unilateral grade IV, 75% 
in bilateral grade IV, 67% in unilateral grade V, but only 31% in bilateral grade 
V (Table 1, bottom). In the CAP group, dilating VUR remained in 30 patients 
(79%) at study exit. The down-grading to VUR ≤ II was seen in infants with 
VUR grade IV (n=6, 40%) and unilateral grade V (n=2, 29%) at baseline, but not 
in any infant with bilateral grade V at baseline (Table 1, bottom). 
 
 
 
  Endoscopy group  Prophylaxis group  
Variable  (n=38)   (n=39)   p-value 
---------------------------------------------------------------------------------------------------------------------- 
Grade of VUR at follow-up    
VUR=0  17 (46%)  6 (16%)  
VUR=I  2 (5%)  0 (0%)  
VUR=II  3 (8%)  2 (5%)  
VUR=III  6 (16%)  7 (18%)  
VUR=IV  4 (11%)  13 (34%)  
VUR=V  5 (14%)  10 (26%)  0.0007 
    
Grade of VUR at follow-up    
VUR grades 0-II 22 (59%)  8 (21%)  
VUR grades III-V  15 (41%)  30 (79%)  0.0014 
    
 Endoscopy group  Prophylaxis group 
                      -------------------------------------------         ---------------------------------------------------- 
VUR grade at follow-up  VUR grade at follow-up 
≤ II > II  ≤ II > II   
Variable  (n=22)  (n=15) p-value (n=8) (n=30)  p-value 
------------------------------------------------------------        ---------------------------------------------------- 
Grade of VUR  
at baseline 
Unilat IV 7 (100%) 0 (0%)  2 (40%) 3 (60%)  
Bilat IV  6 (75%) 2 (25%)  4 (40%) 6 (60%)  
Unilat V 4 (67%) 2 (33%)  2 (29%) 5 (71%)  
Bilat V  5 (31%) 11 (69%) 0.0094 0 (0%) 16 (100%) 0.037 
---------------------------------------------------------------------------------------------------------------------- 
 
Table 1. VUR-grade at the one-year follow-up per treatment group (top) and VUR grade ≤ 
and > II per treatment group, divided by VUR-grade and uni- or bilaterality at baseline 
(bottom). 
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Endoscopic treatment 
Down-grading to VUR grade ≤ II after the first injection was seen in 21 infants 
of 36 analysed per protocol (58%), of whom 12/14 (86%) had VUR grade IV 
and 9/22 (41%) had VUR grade V at baseline. VUR-down-grading was seen in 
another three (67% all together) after the second injection.  
Of the 21 infants with a successful first ET, dilating VUR recurred in four 
(19%), of whom three had bilateral grade V and one had bilateral grade IV at 
baseline (Figure 2). 
 
 
 
Figure 2 Grade of VUR at baseline, after first injection and at 1-year follow-up. The red 
lines representing the four patients with recurrent dilating VUR after a successful first ET. 
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Prediction analyses 
The prediction analysis of VUR outcome in the total study population identified 
ET, VUR grade IV, unilaterality and low PVR at baseline as significant 
predictors with univariable logistic regression. Stepwise logistic regression 
confirmed these predictors in a multivariable model with an area under the ROC 
curve of 0.88 (Table 2). This association is graphically illustrated in Figure 3 
where the decreasing probability of grade ≤ II VUR at one-year correlates with 
increasing PVR, increasing VUR grade, bilaterality and prophylactic treatment.  
 
 
 Univariable Multivariable 
Variable Value 
n (%) of 
event 
OR (95%CI) 
VUR grade  
≤ II vs. > II  
at one-year visit p-value 
OR (95%CI) 
VUR grade  
≤ II vs. > II  
at one-year visit p-value 
Group  ET 22 (59%)     
 CAP 8 (21%) 0.18  
(0.07-0.50) 
0.0010 0.03  
(0.00-0.23) 
0.0007 
VUR grade 
at  
IV 19 (63%)     
baseline* V 11 (24%) 0.19  
(0.07-0.51) 
0.0011   
Bilateral  No 15 (60%)     
VUR Yes 15 (30%) 0.29  
(0.10-0.78) 
0.0144   
VUR grade 
at  
Unilateral 
IV (ref) 
9 (75%) 1.00  1.00  
baseline, 
uni/bi 
Bilateral IV 
vs ref. 
10 (56%) 0.42  
(0.08-2.07) 
0.2846 0.50  
(0.06-3.96) 
0.5120 
 Unilateral 
V vs ref. 
6 (46%) 0.29  
(0.05-1.57) 
0.1491 0.51  
(0.06-4.22) 
0.5312 
 Bilateral V  
vs ref. 
5 (16%) 0.06  
(0.01-0.31) 
0.0007 0.02  
(0.00-0.25) 
0.0023 
Residual  0-<6.4 14 (56%)     
volume  6.4-<16 7 (33%)     
(ml) 16-83.2 6 (25%) 0.96  
(0.92-1.00) 
0.0464 0.92  
(0.86-0.98) 
0.0166 
 
Table 2. Univariable and multivariable prediction of VUR grade ≤ II at the one-year follow-
up in the total study population.  
*Maximum grade in bilateral VUR and duplex.  
Area under ROC curve with 95% CI for multivariable model = 0.88 (0.81-0.96) 
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Figure 3 Stepwise multivariable prediction of VUR grade ≤ II at the one-year follow-up with 
PVR at baseline on the x-axis. Uni- and bilateral VUR separated. Area under ROC-curve = 
0.88. Endo (ET), Prophy (CAP). 
4.1.2 Bladder function 
At baseline, LUTD was seen in 25% (18/72), high BC (from FVO) in 42% and 
high residual in 36%.  
At the one-year follow-up, the BC had decreased in the total study population 
(high capacity in 34%), with no significant difference between treatment groups, 
despite the significantly higher reflux resolution in the ET group (p=0.0014).  
When analysing the bladder variables compared with VUR grade, 
independent of treatment group, PVR at baseline was significantly lower in the 
group with VUR resolution, compared with the non-resolution group (p=0.010) 
[39]. 
 Since the resolution rate of bilateral VUR grade V was low (31% and 0%) in 
both the ET and CAP groups, we evaluated a possible correlation between 
persistent bilateral grade V at follow-up and bladder function. The children with 
persistent bilateral VUR grade V had a larger PVR at baseline and larger bladder 
capacity at the one-year follow-up (p=0.0073 and p=0.016), as illustrated in 
Figure 4.  
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Figure 4 Functional bladder capacity (A) and residual urine (B) at baseline (blue) and the 
one-year follow-up (red) in infants with high-grade VUR. Grouping variable VUR at the 
one-year follow-up. The box plot shows from the bottom: minimum, 25th percentile, median, 
mean, 75th percentile, maximum and outlier. 
In the explanatory analyses of bladder function vs. outcome, we identified large 
PVR at baseline as a predictor of VUR grade > II at follow-up, bilateral grade V 
VUR at follow-up, and recurrent UTI (p=0.046, 0.022 and 0.034).  
A 
B 
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Moreover, large BC at follow-up, was seen in infants with remaining bilateral 
grade V VUR (p=0.025/p=0.027) and in infants with new/progress in existing 
renal damage (p=0.006) (Table 3).  
 
 
Probability of 
having 
VUR grade >2 
at one-year 
Probability of 
having bilateral 
VUR grade 5 
at one-year 
Probability of 
having febrile UTI 
during the study 
until one-year 
Probability of having 
new/progress in 
renal damage  
at one-year 
Explanatory 
variables 
OR  
(95% CI) p-value 
OR  
(95% CI) 
p-
value 
OR  
(95% CI) p-value 
OR  
(95% CI) p-value 
Baseline  
BC, % of expected 
for age  
Continuous variable 
1.14 
(0.97-
1.34) 
0.12 1.17 
(0.99-
1.39) 
0.060 1.10 
(0.94-
1.27) 
0.22 1.00 
(0.80-
1.24) 
1.00 
BC, % of expected 
for age 
≥ 150% vs < 150% 
2.73 
(0.96-
7.78) 
0.061 2.02 
(0.55-
7.40) 
0.29 1.29 
(0.41-
4.06) 
0.66 1.16 
(0.24-
5.63) 
0.86 
Residual volume (ml)  
Continuous variable 
1.23 
(1.00-
1.50) 
0.046 1.22 
(1.03-
1.45) 
0.022 1.19 
(1.01-
1.39) 
0.034 1.15 
(0.95-
1.38) 
0.15 
Residual volume  
≥ 20ml vs < 20ml 
3.86 
(0.99-
15.03) 
0.051 3.26 
(0.85-
12.53) 
0.085 2.50 
(0.74-
8.41) 
0.14 4.92 
(0.98-
24.82) 
0.053 
Lower urinary tract 
dysfunction  
(number) 
3.86 
(0.99-
15.03) 
0.051 3.26 
(0.85-
12.53) 
0.085 2.50 
(0.74-
8.41) 
0.14 4.92 
(0.98-
24.82) 
0.053 
One-year follow-up 
 
BC, % of expected 
for age  
Continuous variable 
1.19 
(1.00-
1.43) 
0.050 1.26 
(1.03-
1.54) 
0.025 1.10 
(0.93-
1.30) 
0.26 1.38 
(1.10-
1.73) 
0.006 
BC, % of expected 
for age 
≥ 150% vs < 150% 
1.79 
(0.61-
5.24) 
0.29 4.67 
(1.19-
18.26) 
0.027 3.38 
(1.00-
11.39) 
0.050 3.04 
(0.62-
14.99) 
0.17 
Residual volume (ml)  
Continuous variable 
1.03 
(0.93-
1.14) 
0.54 1.09 
(0.97-
1.21) 
0.15 1.01 
(0.90-
1.13) 
0.86 1.13 
(1.00-
1.27) 
0.051 
Residual volume  
≥ 20ml vs < 20ml 
1.12 
(0.40-
3.15) 
0.83 1.08 
(0.28-
4.17) 
0.91 2.12 
(0.64-
7.00) 
0.22 2.81 
(0.57-
13.81) 
0.20 
Lower urinary tract 
dysfunction  
(number) 
1.56 
(0.50-
4.83) 
0.45 1.67 
(0.43-
6.59) 
0.46 2.31 
(0.67-
7.89) 
0.18 2.20 
(0.44-
10.98) 
0.34 
 
Table 3 Explanatory analyses of bladder variables in patients with VUR grade 
> 2 at follow-up, bilateral VUR grade 5 at follow-up, febrile UTI during the 
study and progress in existing renal damage. Significant p-values in bold text. 
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4.1.3 UTI and renal damage 
Baseline 
At inclusion, 67/77 children (87%) had renal parenchymal defects on 
scintigraphy. The damage was more generalised in boys and only 7% of the boys 
had a normal baseline scintigraphy (p=0.0097) (Fig 5).  
 
 
 
Figure 5 Bar chart showing renal damage at baseline, number and percentage, in boys 
versus girls. Light blue indicates none and focal damage, dark blue indicates multifocal or 
generalised damage 
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When analysing the correlation between the character of renal damage at 
baseline and VUR grade per renal unit, we found that 26 of 32 renal units (81%) 
with VUR 0-II at baseline had normal renal scans. Generalised renal damage was 
only seen in the renal units with dilating VUR at baseline (Table 4). 
 
. 
 Girls Boys 
Variable 
VUR grades  
0-II at  
baseline 
VUR grades  
III-V at  
baseline 
p-
value 
VUR grades  
0-II at  
baseline 
VUR grades  
III-V at  
baseline 
p-
value 
 n=10 RU n=34 RU  n=22 RU n=87 RU  
Character of 
renal damage 
at baseline 
      
None       9 (90%) 17 (50%)  17 (81%) 28 (33%)  
Focal      1 (10%) 10 (29%)  3 (14%) 19 (22%)  
Multifocal 0 (0%) 2 (6%)  1 (5%) 3 (4%)  
General    0 (0%) 5 (15%) 0.045 0 (0%) 36 (42%) 0.0005 
 
Table 4 The character of renal damage at baseline, analysed per renal unit (RU) and divided 
by VUR grade 0-II/III-V at baseline. 
 
Moreover, bilateral renal parenchymal defects at baseline were correlated with a 
lower GFR, median 72% (44-109) vs 97% (43-140) of expected (p=0.0067). 
Fifty-nine of 77 infants had a history of UTI already at inclusion, whereof 33 
(56%) were caused by non-Escherichia coli, with no difference between boys 
and girls. Incidentally, the proportion of index UTI with non-E. coli was larger 
in the CAP group. 
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Follow-up 
UTI 
There were 27 febrile UTIs registered in 16 patients during the study, with no 
difference between the ET and CAP group (6 vs. 10), but more frequent in girls 
(8/22, 36%) than in boys (8/55, 15%). Univariable logistic regression showed 
that female sex and a high PVR at baseline was predictive of febrile UTI 
(p=0.039 and p=0.034), independent of treatment group. Explanatory analyses 
also showed that infants with high grade VUR at follow-up had a higher 
incidence of febrile UTI (p=0.042) (Table 5). 
 
 
Variable 
n  
missing Value 
Probability of having febrile 
UTI during the study  
Probability of having renal 
deterioration at follow-up 
 n (% of 
event) 
OR 
 (95%CI) 
p-
value 
n (% of 
event) 
OR 
(95% CI) 
p- 
value 
B
as
e
lin
e
 Group  0 ET 6 (16%)   3 (8%)   
  CAP 10 (26%) 1.84  
(0.59-5.69) 
0.29 5 (14%) 1.72  
(0.38-7.79) 
0.48 
Sex 0 Girls 8 (36%)   4 (19%)   
  Boys 8 (15%) 0.30 
(0.09-0.94) 
0.039 4 (8%) 0.35  
(0.08-1.57) 
0.17 
Grade of VUR 0 VUR=IV 6 (20%)   2 (7%)   
at baseline  VUR=V 10 (21%) 1.08  
(0.35-3.36) 
0.89 6 (14%) 2.13  
(0.40-11.38 
0.38 
BC at 
baseline  
5 Per 20 % of 
expected 
increase 
 1.10  
(0.94-1.27) 
0.22  1.00  
(0.80-1.24) 
1.00 
PVR at 
baseline  
5 Per 1 ml 
increase 
 1.19  
(1.01-1.39) 
0.034  1.15  
(0.95-1.38) 
0.15 
  Categorised 
≥ vs. < 20ml 
 2.50  
(0.74-8.41) 
0.14  4.92  
(0.98-24.82 
0.053 
O
n
e-
ye
ar
 f
o
llo
w
-u
p
 Grade of  2 VUR=0 2 (9%)   0 (0%)   
VUR at   VUR=I 0 (0%)   0 (0%)   
one year  VUR=II 1 (20%)   0 (0%)   
  VUR=III 3 (23%)   2 (15%)   
  VUR=IV 5 (29%)   4 (25%)   
  VUR=V 5 (33%) 1.41  
(1.01-1.98) 
0.042 2 (15%) 1.85  
(1.03-3.35) 
0.041 
Febrile UTI 
during study  
0 No UTI -   2 (4%)   
  Any UTI - - - 6 (33%) 13.25 (2.38-
73.89 
0.003 
BC at  
one year 
10 Per 20 % of 
expected 
increase 
 1.10  
(0.93-1.30) 
0.26  1.38  
(1.10-1.73) 
0.006 
PVR at  
one year  
10 Per 1 ml 
increase 
 1.01  
(0.90-1.13) 
0.86  1.13  
(1.00-1.27) 
0.051 
Table 5 Explanatory analyses of febrile UTI and renal deterioration. Significant p-values in 
bold text. 
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During the study, there were 16 recurrences (59%) with non-E. coli and 11 with 
E. coli. Most recurrences (22/27) occurred during CAP, with bacteria resistant to 
the given prophylaxis. Multiple recurrences were only seen in patients with 
remaining dilating reflux at follow-up (p=0.019) (Fig. 6). 
 
Figure 6 Bubble plot of the number of febrile recurrent UTIs during the study versus VUR 
grade at one year. The sizes of the circles are related to the number of patients. Multiple 
recurrences were only seen in patients with remaining dilating reflux at follow up. 
 
4.1.4 Renal damage 
Deterioration on scintigraphy at the one-year follow-up was noted in eight 
children (nine kidneys), with no difference between treatment groups (p=0.48). 
Seven had progress in old damage (three with additional new scars) and one had 
a new scar in a previously undamaged kidney. Explanatory analyses showed that 
6/8 had one or more febrile UTIs between the first and second scintigraphy, 
demonstrating that UTI increases the probability of renal deterioration (p=0.003) 
(Table 5). None of the tested baseline variables was able to predict renal 
deterioration, but high PVR appeared to be important (p = 0.053). However, 
renal deterioration did correlate with both dilating VUR (p=0.041) and high BC 
(p=0.006) at follow-up (Table 5). 
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4.1.5 Adverse events Papers I-III 
Five children changed treatment arms for reasons listed in the CONSORT flow 
chart, included in Appendices and in Paper I [23].  
Four patients required ureteral re-implantation; one with remaining dilating 
VUR and impaired renal function after two injections, one because of an 
obstruction after injection and two because of VUJ stenosis detected at 
cystoscopy (not injected). No adverse events were reported during or after 
anaesthesia.  
The prophylaxis was changed from nitrofurantoin to another agent in three 
patients, due to nausea and/or vomiting. No other side-effects were reported in 
the CAP group.  
During the study, 164 invasive procedures (112 VCUG and 52 cystoscopies) 
were performed. We saw only one febrile UTI possibly related, which occurred 
15 days after ET (Figure 7).  
 
 
 
 
 
 
Figure 7 
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4.2 Results paper IV 
Four focus group discussions were conducted with 13 mothers and six fathers of 
15 children. The demographic data on the informants are listed in Appendices. 
The children were aged 1.5-6 years at the time of the focus groups. They had all 
been diagnosed with VUR grade IV or V (47%/53%) before the age of six 
months. Ten had bilateral reflux (67%), and nine were male (60%). Eight 
children had been treated with CAP (groups 1-2) and seven children with CAP 
and SI (groups 3-4). Five children had an antenatal diagnosis of hydronephrosis, 
one was screened because of heredity and nine presented with a UTI (Table 6). 
 
FG Informant Parent’s 
sex 
Child’s age 
at time of 
interview 
(years) 
Child’s 
sex 
Grade of 
VUR 
Treat-
ment 
Debut of 
VUR 
1 1 f 3,5 m Bilat 4 CAP UTI 
2 f 4,5 m Bilat 5 CAP AHa 
3 m 2 f Bilat 5 CAP UTI 
41 f 4 f Bilat 4 CAP Heredity 
51 m 4 f Bilat 4 CAP Heredity 
2 6 m 2 f Unilat 4 CAP UTI 
7 f 1,5 m Bilat 5 CAP AHa 
8 f 4 m Bilat 5 CAP UTI 
9 f 4 m Unilat 4 CAP AHa 
3 102 f 6 m Unilat 5 Open 
surgeryc 
UTI 
113 m 6 f Bilat 4 ET AHa 
123 f 6 f Bilat 4 ET AHa 
132 m 6 m Unilat 5 Open 
surgeryc 
UTI 
14 f 2,5 m Bilat 4 ET UTI 
4 154 f 4 m Unilat 5 Open 
surgeryb 
AHa 
16 f 6 m Bilat 5 ET UTI 
17 f 4,5 f Unilat 5 Open 
surgeryb 
UTI 
18 f 3 f Bilat 4 ET UTI 
194 m 4 m Unilat 5 Open 
surgeryb 
AHa 
 
Table 6 Sample characteristics. Information on the 15 children of the 19 informants. 
1, 2, 3, 4 Both parents participating in the same focus group (FG), light grey child is 
represented by two parents. 
 a antenatal hydronephrosis, b ureteric re-implantation, c partial nephrectomy 
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A total of 2,897 statements on the parents’ experiences of hVUR were identified 
during the analysis process. These statements were sorted into 10 categories 
(Figure 7). In this study, we focused on the parents’ experiences of CAP, SI, 
UTI and renal damage. These four main topics generated 1,123 statements (39% 
of all), categorised into nine categories and 33 sub-categories. The main 
categories and subcategories of CAP, SI, UTI and renal damage are listed in 
Table 7 in descending order, according to the frequency of the described 
experience.  
 
 
 
Figure 7 Number of statements (n=2,897), divided by category.  
*The four main topics of the study. 
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Categories and sub-categories Frequency 
UTI 535 (48%) 
Family impact due to the child’s UTI  
-Restricted social family activities due to ongoing UTI or fear of 
other infection 
-Emotional stress and worries about the risk of UTI 
-Difficulties differing between UTI and other infection 
-UTIs are fewer and easier to recognise with increased child age 
-Always being prepared to seek immediate medical care  
-Frequent visits to the emergency department during infancy 
-Family strains when the child is admitted to hospital 
273 (24%) 
76 
50 
48 
39 
31 
22 
7 
Emergency care at suspected UTI of the child 
-Long waits and stressed staff in the emergency department 
-Determination of need for treatment and level of care 
-Friendly, fast management in the emergency department 
-Parents not being heard and symptoms not taken seriously in 
the emergency department 
-Inaccessible primary health care  
-Difficulties with blood samples and iv lines in urgent situations 
131 (12%) 
36 
34 
25 
13 
12 
11 
Obstacles and facilitators of sampling and testing of urine 
-Difficulties collecting a urine sample 
-Challenges handing in a urine sample for analysis 
-Challenges convincing caregivers to perform a urine culture 
-Facilitators of sampling and testing of urine 
131 (12%) 
44 
32 
26 
29 
CAP 320 (28%) 
Emotional stress about the child’s CAP intake 
-Stress making the child take the CAP 
-Stress about the responsibility/worry if the intake of CAP fails 
140 (12 %) 
103 
37 
Worries and uncertainties regarding the effects of CAP 
-Worries about the long-term use of CAP 
-Thoughts about the therapeutic effect of the CAP 
-Negative influences on the child’s intake of food and other 
meds 
140 (12 %) 
50 
46 
44 
The CAP intake was unproblematic 40 (4%) 
SI 182 (16%) 
Difficulties associated with SI 
-Distress seeing the child at the induction of anaesthesia 
-Inadequate information and insufficient personal treatment 
-Difficulties parenting in the postoperative care environment 
-Troublesome pre-operative preparations 
-Long waits during surgery 
94 (8%) 
30 
23 
20 
15 
6 
Positive experiences related to SI  
-Professional and personal treatment in anaesthesia and surgery 
-Safe postoperative management 
-Unproblematic pre-operative preparations 
88 (8%) 
66 
19 
3 
Renal damage 86 (8%) 
Risk of renal damage 
-Worries about the risk of renal damage 
-No worries about the risk of renal damage 
-Existing renal damage 
86 (8%) 
44 
27 
15 
Table 7 Parents’ experiences (n=1,123) in descending order according to frequency of statements 
per category and subcategory. 
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4.2.1 Experiences of CAP (n=320) 
Forty (13%) of the CAP experiences were positive, stating that the intake of 
CAP was unproblematic. The remaining 280 statements described negative 
experiences, of which the majority (n=103) related to parents’ every-day stress 
when getting their child to take the antibiotics. Other sub-categories regarded 
parents’ stress about the treatment responsibility and concern about missing a 
CAP dose (n=37), worries about the long-term use (n=50) and thoughts about 
the therapeutic effect of CAP (n=46). The negative influence on the children’s 
food preference was a matter of concern in all focus groups (n=44). 
4.2.2 Experiences of SI (n=182) 
Parents’ experiences of anaesthesia and surgical care were both positive (n=88) 
and negative (n=94).  The experiences were positively affected by empathic 
treatment, accurate information and adequate preparation. Among the negative 
experiences, inadequate information and a feeling of helplessness at the 
induction of anaesthesia were among the most frequently described concerns. 
Difficulties parenting in the postoperative care environment were mostly caused 
by parents being poorly prepared.  
4.2.3 Experiences of UTI (n=535) 
The majority of parents’ experiences of UTI reflected strain (n=408), where 
most statements described a negative family impact due to UTI, such as 
restricted social activities and the emotional stress associated with the constantly 
present risk of UTI.  
The experiences of emergency care at suspected UTI encompassed long 
waiting times, stressed staff and a feeling of not being heard, but also positive 
experiences of fast, friendly management.  
The sampling and testing of urine is a frequent issue for these families; 
waiting for the child to pee, convincing caregivers, not only to accept the urine 
sample, but also to perform a urine culture. Among facilitators of urine testing, 
parents suggested better access to primary care, possibility leaving urine samples 
at an open clinic and having tubes for urine samples at home. 
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4.2.4 Experiences of renal damage (n=86) 
Parents’ thoughts about renal damage varied considerably, both between and 
within the groups. While 44 statements expressed a constant worry over the risk 
of renal damage and impaired renal function, 27 described no concern over their 
children’s kidneys. The remaining 15 statements described, in a fairly neutral 
tone, an awareness of existing renal damage.  
 
 
 
 
 
 74    
 
 
  
5 .  DISCUSSION 75  
5. Discussion 
VUR outcome 
The Swedish infant high-grade reflux trial is the first randomised study 
comparing endoscopic treatment with antibiotic prophylaxis in infants with VUR 
grades IV-V. We found a significantly higher resolution rate in infants treated 
with ET than in the CAP group and we were able to confirm that the treatment is 
safe, with few complications even in this young age group. The success rate of 
ET was related to VUR grade and uni- or bilaterality. ET in VUR grade V has 
been described previously, but it is not common practice. This study reported 
fair results in unilateral VUR grade V (65%), but less favourable results in 
bilateral cases (31%).  
In children with a successful first ET, there was a recurrence of dilating VUR 
in 19%, which is in agreement with previous studies [59, 61]. 
When discussing VUR outcome, it is essential to take the aspect of 
spontaneous resolution into account. Even if the rate is lower in higher VUR 
grades (38-48% in grade IV) [28, 29], it is still a factor to consider and early ET 
treatment should only be recommended in patients with breakthrough infections 
and a risk of renal deterioration [43] [45] [21]. Furthermore, infants with 
megaureter can have both VUR and stenosis, which must be ruled out before 
suggesting ET.  
If a reduction in VUR grade is desired and obstruction is excluded, we regard 
ET as a safe and attractive first-line alternative, despite the recurrence rate. ET 
can buy the family and the treating physician time, until the child is less prone to 
recurrent UTIs and more suitable for other surgical procedures [62, 63].  
Bladder function 
This study was not able to prove that early endoscopic treatment is superior to 
prophylaxis in preventing LUTD in infants with high-grade VUR. Instead, we 
found that bladder function differs from the start and is probably a part of the 
congenital VUR anomaly. Although, the decrease in bladder capacity in children 
with non-dilating VUR at follow-up might indicate that refluxing urine still has a 
role to play in the development of high BC. 
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High PVR at baseline was an independent negative predictor of VUR 
resolution in both treatment groups. More interestingly from the clinical point of 
view, high PVR at baseline also merged as a predictor of recurrent UTI and renal 
damage at the one-year follow-up. The correlation between LUTD and a lower 
probability of VUR resolution has previously been shown [21, 116-119] and also 
that increased PVR correlates with recurrent UTI in infants with hVUR [37, 
120].  
The question of whether PVR in high-grade VUR actually is reflux urine and 
that it is therefore related to the grade of VUR rather than to bladder dysfunction 
has been discussed. According to this study, PVR increased in both resolution 
and non-resolution groups, which contradicts the hypothesis that PVR mainly 
consists of reflux urine. In the children investigated with videocystometry, we 
were also able to demonstrate that PVR consisted of pure reflux urine in a very 
few patients. In most cases, it was a mixture of both. Whether PVR is reflux 
urine or true residual or a combination of both is less important, since it is the 
incomplete bladder emptying that is the risk factor for rUTI and possibly new 
renal damage. 
Shaikh et al. evaluated the effect of bowel and bladder dysfunction on 
recurrent UTI in children with and without VUR [121]. They analysed the data 
from the two longitudinal studies, RIVUR [122] and CUTIE (careful urinary 
tract infection evaluation). In both studies, the inclusion criterion was UTI in 
children aged two to 71 months and, if VUR grades I-IV was diagnosed, the 
child was included in the RIVUR trial, with randomisation to CAP or placebo, 
and, if there was no VUR, the child was included in the CUTIE trial with no 
treatment. The two trials comprised a total of 802 children from which Shaikh et 
al. analysed a sample of 181 children who were toilet trained and had data for 
baseline BBD. Among these, only four were boys and 97 (54%) had BBD at 
baseline, with no difference between children with and without VUR (p=0.15). 
In VUR patients with placebo, BBD was associated with a higher rate of rUTI 
(51% with BBD vs. 20% without BBD, p=0.01). Conversely, in VUR patients 
with CAP and in patients without VUR and no treatment, the rates of rUTI were 
similar with and without BBD. In none of the three cohorts was BBD associated 
with renal scarring, possibly due to the rarity of this event in the cohorts and 
thereby with limited power to detect differences.  
UTI and renal damage 
We found no difference in the rate of recurrent UTI or renal deterioration 
between the two treatment groups in this study. Although, we did see a higher 
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frequency of UTI recurrences in children with persisting dilating VUR at follow-
up. This fact, in combination with the higher resolution rate in the ET group, 
may still indicate a potential benefit of treating hVUR endoscopically in infants.  
The prevalence of renal parenchymal defects of 87% at baseline in this study 
with 71% boys, corresponds well with the concept that early clinical 
manifestation indicates a more severe disease, especially in males. The renal 
damage was strongly correlated with the grade of VUR and was more common 
and more severe in boys. Similar findings have been reported in previous studies 
of congenital renal dysplasia in boys versus acquired renal scarring due to febrile 
UTI in girls [20, 123, 124].  
Moreover, we found that febrile UTIs were more likely to occur in girls than 
in boys (p=0.039), which was also seen in the Swedish reflux trial. The Swedish 
reflux trial also found that the UTI rate in girls was higher in the surveillance 
group compared with both CAP and endoscopy. The rate of new renal damage 
was also higher in the surveillance group in girls, while there were no effects of 
CAP on UTI recurrence or renal damage in boys [49, 50].  
In this study, renal deterioration was found in eight children (10%), 
significantly related to recurrent UTI and VUR grade on the scarred renal unit, 
but with no difference between CAP and ET. It is important to mention that the 
study was not designed to detect differences of this kind between the groups. It 
is also possible to discuss whether a larger study population or a longer follow-
up would have changed the outcome. However, neither the International reflux 
study in children (aged 0-10 years) [48, 125] nor the Birmingham reflux trial 
(aged 0-15 years) [126] found any difference in renal scarring or UTI recurrence 
between CAP and open surgery. Similar to our results, previous studies have 
also identified hVUR as a risk factor for renal scarring after a febrile UTI [127, 
128].  
Some authors have started to question whether VUR really predisposes to 
UTI and renal damage [129], but this mainly relates to lower grades of VUR in 
older children. So, despite the fact that two RCTs failed to detect a difference in 
UTI recurrence between children with and without VUR, it is important to 
consider that all ages were mixed in the analyses and all grades of VUR were 
included in one [51] and only grades I-III in the other [130]. So, even if there is 
no convincing evidence that VUR predisposes to renal scars in UTI patients with 
non-dilating VUR, conclusions cannot be drawn regarding VUR grades IV and 
V due to a lack of available data [129].   
Moreover, the effectiveness of CAP in preventing febrile UTI has been 
questioned [131-133]. Mattoo et al. performed a meta-analysis of five 
randomised studies comparing CAP with surveillance or placebo in a total of 
809 patients with VUR [29, 51, 130, 134, 135], which revealed no benefit from 
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prophylaxis in preventing UTI or renal scarring [136]. However, the results 
should be interpreted with caution, because the study populations differ 
considerably and most studies excluded children with high-grade VUR. Further, 
two large trials of CAP and UTI had not yet been analysed and published and 
were therefore not included in the meta analysis. Firstly, the RIVUR study, 
where CAP reduced UTI recurrences by 50% [30]. Secondly, the Swedish reflux 
trial, where they found a significantly higher recurrence rate among girls in the 
surveillance group (57% compared with 19% on CAP and 23% with ET) [49]. 
What do parents think? 
Many parents in the focus groups described the hesitation they felt when giving 
antibiotics to their child, both uncertain of the therapeutic effect and scared of 
long term effects and the risk of increasing bacterial resistance. The concerns 
about the actual intake and the stress related to the responsibility further 
increased their reluctance about CAP.  
The parents’ hassle relating to daily medication administration should not be 
underestimated. There is a common belief that CAP is the “easy” treatment 
option and planning for surgical or endoscopic treatment is often a major 
decision.  
When listening to the parents in this study, however, negative experiences of 
CAP were commonly described (88% of all CAP statements), while the negative 
experiences of surgical intervention (52% of all SI experiences) were related to a 
single occasion and could be eased with adequate preparation, information and 
an empathetic approach.  
In studies of parents’ preferences, Tran et al. identified 13 themes that 
influenced the parents’ choice of VUR treatment. The four most common were 
the prevention of future UTI, the efficacy rate of treatment, the burden of daily 
maintenance and the risk of antibiotic resistance [137]. Capozza et al. evaluated 
parental treatment preferences in children with VUR grade III who had been on 
CAP for at least six months. After detailed information about the three treatment 
options (CAP, ET and open surgery), 80% of all parents would prefer ET [138]. 
In other studies, the success of the procedure has been regarded as the most 
important factor for parental satisfaction [69, 70] and increased HRQoL [68, 
139]. 
It was also evident, when analysing the discussions, that the UTI outcome is 
of great parental relevance. Not surprisingly, the majority of UTI experiences 
were negative and challenges appeared in different circumstances. The 
restriction of social activities due to ongoing UTI or the parents’ fear of other 
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infections were frequently described, as were the challenges involved in 
differentiating between UTI and other infections. Parents’ reports on the 
difficulty associated with handing in a urine sample and obtaining a culture can 
be relieved by the healthcare system. According to our study results, better 
access to primary care and the opportunity to leave a urine sample at an open 
clinic, would facilitate the lives of these families considerably.  
The daily negative impact of CAP and UTIs on family life was evident in this 
study, but it was not identified in previous studies of VUR and HRQoL. One 
reason for this could be our study material relating to infant high-grade VUR, 
but also the fact that the methods previously used were not sufficiently sensitive 
to capture the challenges in these families [66, 140].  
In contrast, the parents expressed very little concern about renal damage. Most 
of the parents were aware that their child had renal damage and that a febrile 
UTI could cause further scarring. Some of them stated that this knowledge 
increased their fear of UTIs, but it appeared that in most cases the treating 
physician had managed to calm them down with the information that “you only 
need one kidney”. The lack of consistency in parents’ experiences of renal 
damages does not make any experience wrong or the result less valid. Instead, it 
offers an insight into diversity and tells us that the participants dare to have 
opinions of their own. 
 
When evaluating the quality of this focus group study, one can conclude that we 
studied experiences of parents to a special sub-group of VUR patients (infants 
with VUR grades IV-V), stratified for treatment (CAP or SI) with focus on a 
very limited period of the children’s lives (0-2 years of age), which gained 
homogenous groups and facilitated the data collection. By stratifying for sex and 
pre/postnatal diagnosis we aimed to achieve external representativeness of 
infants with hVUR [89].  
With the focus group manual, the same questions were asked in all focus 
groups, which increased the study’s dependability. The data were categorised by 
two researchers through a reflective, back-and-forward sorting process in order 
to limit selection bias and to increase the validity and the credibility of the 
process [92]. The credibility, but also the transferability, was further enhanced 
by a rich presentation of the findings together with representative quotes [89, 
94]. Moreover, the use of tables, describing the research process, can aid other 
researchers to review the different steps of the process, which further 
strengthened the trustworthiness of the study.  
Category saturation is reached when researchers gather data to the point 
where no new information is being added [141], and was in this study confirmed 
through comparison analysis of multiple focus groups.  
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Importantly, none of the moderators had been involved in the previous care or 
treatment of the informants’ children, which is crucial for the focus group 
dynamics and complies with the Oxford critical appraisal of qualitative studies 
[142]  . 
The most vulnerable children 
It is important to acknowledge bilateral VUR grade V as a more extensive 
congenital anomaly, often with renal hypo/dysplasia, a high morbidity rate and a 
high risk of recurrent UTI. The condition almost exclusively affects boys and 
presents during infancy, either in the follow-up after antenatal hydronephrosis or 
after an early febrile UTI.  
The prognosis is far worse compared with lower grades of VUR and, in our 
study, only five of 34 cases of bilateral grade V had resolved at follow-up. All 
five infants with reflux resolution had normal bladder parameters and they had 
all been treated with endoscopic injection.  
These children pose a true challenge when it comes to managing their treatment 
and follow-up. 
Strengths and weaknesses 
The Swedish infant high-grade reflux trial was a randomised, controlled trial, 
with a selection of high-risk VUR patients, previously excluded from most 
studies. The recruitment was initially slow, due to the low prevalence of VUR 
grade V, but also because many eligible infants were excluded when 
vesicoureteral obstruction could not be ruled out. Nonetheless, the power-
calculated number of participants was reached, based on the primary outcome of 
VUR resolution and bladder function.  
In spite of this, the number of patients in each treatment arm was relatively 
small and the follow-up time was short. With a larger study sample and a longer 
follow-up, we might have been able to detect a difference in rUTI and renal 
damage between the treatment groups. In addition, the low success rate of ET in 
bilateral VUR grade V probably contributed to the finding that no difference in 
bladder function between the treatment groups was seen and that we were unable 
to find a statistical correlation between ET and recurrent UTI.  
Moreover, information about the eligible patients who declined participation 
or were excluded has not been registered.  
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Another limitation of this study is that the type of bacteria in the index UTI was 
not taken into account in the randomisation procedure. By chance, there was a 
larger proportion of non-E. coli-caused index UTIs in the CAP group and we do 
not know if this affected the outcome of UTI and renal deterioration. 
 
The sample size of the focus group study was adequate according to focus group 
methodology [143] and the study was carefully designed according to current 
standards, such as involving the target population in evaluation of health care 
[76, 81, 144]. The study design also complied with the Oxford critical appraisal 
of qualitative studies [142] and was strengthened by using population 
characteristics consistent with VUR IV-V infants (3:1 male predominance and 
1/3 diagnosed after antenatal hydronephrosis) [20, 62]. If the parents of the same 
family wanted to participate in the same focus group, this opportunity was given. 
Therefore, in some cases, the child was represented by two parents. A main 
reason to give this choice is that it may facilitate the participants’ sense of 
security in the focus group, which is essential for the respondents’ openness and 
provision of reliable information. And even if two parents represent one family, 
and one child, they still have their own individual experiences. Moreover, the 
moderator assured that all participants had an opportunity to contribute and that 
no one dominated the discussion. 
Focus group methodology has its limitations: participants may give socially 
desirable responses and the level of the discussion may not reach the desired 
depth. All individuals make different numbers of statements and the findings 
therefore reflect the group rather than the participants [145]. An increased 
number of statements may indicate the high relevance of an issue, but it cannot 
be used either to generalise the finding or to determine the actual difference 
between groups and the extent to which participants are affected by the issue.  
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6. Conclusion 
High-grade VUR in infants can be treated with injection therapy and the 
resolution rate is higher compared with CAP treatment. ET can be suggested as a 
safe and effective treatment in infants with VUR grade IV and unilateral grade 
V. It can also be offered in bilateral grade V, in cases with normal bladder 
function, where active treatment is necessary. 
We were not able to prove that LUTD can be prevented by early VUR 
resolution, but it can instead be seen as a part of the congenital VUR 
abnormality. High PVR, as a sign of bladder dysfunction, is an important 
prognostic factor for VUR outcome in both prophylactic and endoscopic 
treatment. 
There was no difference in UTI recurrence or renal deterioration between the 
treatment groups. The VUR grade at follow-up correlated with both recurrent 
UTI and renal deterioration. Female sex and bladder dysfunction, especially high 
PVR, and are positive predictors of UTI recurrences. 
The focus group study revealed that both CAP and the risk of UTI have a 
non-negligible, everyday impact on family life, while renal damage appears to be 
of secondary importance to the parents. The parents’ concerns in terms of SI are 
related to an isolated occasion, which can be optimised by simple means.  
 
The management of VUR should be evidence based and risk adapted based on 
the child’s age, sex, reflux grade, history of UTI, renal function and associated 
bowel/bladder dysfunction – with parents’ preferences taken into consideration. 
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7. Future perspectives 
Our results show that endoscopic treatment is a safe and effective treatment 
alternative in infants with high-grade VUR, particularly in grade IV and 
unilateral grade V, but also in selected cases of bilateral grade V. We have 
highlighted the importance of risk grading even among the hVUR patients, to 
decide what patient would benefit from early intervention. Given how important 
bladder dysfunction appears to be for the prognosis of VUR, bladder evaluation 
should be included in the basic investigations. 
Concerns regarding the use of antibiotic prophylaxis, with the risk of 
resistance development, the daily burden of medication administration and the 
prophylaxis-driven need for repeated renal imaging call for further research 
regarding the role of CAP in general VUR management. This study did not 
evaluate the effect of CAP, as the children in the ET group also had CAP until 
VUR resolution. So, regarding high-grade VUR, no study has yet proven that 
surveillance is an alternative management form in these children. Randomised 
studies are needed both to investigate which patients with VUR grades IV and V 
will benefit from prophylactic antibiotics and to identify factors that contribute 
to UTI recurrence and renal parenchymal scars. The results from the focus group 
study demonstrate the parents’ need for more information and clearer guidance, 
which hopefully new studies will be able to provide.  
There is also a need to continue questioning the use of invasive investigations 
and encourage the development of alternative modalities for VUR grading. For 
VUR grades I and II, repeated VCUG is not needed, but the prompt treatment of 
any episode of recurrent UTI is recommended. However, in VUR grades III-V, 
especially grades IV and V, VCUG still has a role to play in detecting 
spontaneous resolution and, in combination with renal imaging, in choosing the 
optimal treatment regimen. 
 
This research project was only able to accommodate a small part of the results 
from the focus group study. The remaining results regarding parents’ 
experiences from the time of diagnosis, diagnostic procedures, remaining family 
impact and coping mechanisms are yet to be presented. In addition, parents’ 
experiences of the health care that is given, including information, accessibility, 
personal treatment, continuity and much more besides, will hopefully bring 
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useful knowledge to the discussion about VUR management and patient-centred 
care. 
 
A long-term follow-up study of the Swedish infant high-grade reflux trial, from 
the same research centre with the same study cohort, has recently been proposed. 
It is to be hoped that it will shed light on some of the study’s remaining 
questions: did ET affect the rate of UTI recurrence or renal damage in the long 
term, have there been any late complications of ET such as obstruction, what is 
the long-term result of ET in relation to hVUR and have any late surgical 
procedures been performed? 
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 Assessed for eligibility (not registered) 
Excluded (not registered) 
-   Not meeting inclusion criteria  
-   Declined to participate 
-   Other reasons  
Analysed PP (n=36)  
- Excluded from analysis (n=4)  
4 who did not receive allocated 
intervention 
- Added to analysis (n=2) 
2 imported from prophylaxis group  
Analysed ITT (n=37) 
- Excluded from analysis (n=1)  
1 reimplantation before ET (protocol 
violation) 
Lost to follow-up (n=0) 
Discontinued intervention (n=2) 
2 re-implantations after ET (LOCF) 
Allocated to endoscopic therapy (n=38) 
- Received allocated intervention (n=34) 
- Did not receive allocated intervention 
(n=4) 
 1 VUJ stenosis detected at cystoscopy 
1 delayed treatment and 
spontaneous resolution 
1 parents declined therapy  
    3 change of treatment arm 
1 VUJ stenosis detected at cystoscopy 
     1 re-implantation  
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to antibiotic prophylaxis alone 
(n=39) 
- Received allocated intervention (n=37) 
- Did not receive allocated intervention 
(n=2) 
 2 change of treatment due to 
parents’ request 
Analysed PP (n=39)  
- Excluded from analysis (n=3)  
2 who did not receive allocated 
intervention 
1 VCUG at follow-up not assessable 
- Added to analysis (n=3) 
3 imported from endoscopy group 
Analysed ITT (n=38) 
- Excluded from analysis (n=1)  
VCUG at follow-up not assessable 
Allocation 
Analysis 
Follow-up 
Enrolment 
Randomised 
(n=77) 
CONSORT flow diagram 
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Focus group manual 
1. Describe how it was for you, as parents or parents-to-be, when your 
child had the diagnosis VUR (or hydronephrosis)?  
2. Children with VUR go through many diagnostic procedures, 
occasionally with catheter or i.v. line and sometimes blood samples 
and urine samples are needed.  
How did you experience this and how did this affect you and your 
child? 
3. Infants with high-grade VUR need to take continuous antibiotic 
prophylaxis to prevent UTI. Describe how this regular medication 
affected you and your daily life. 
4. Despite the CAP, the child can get a breakthrough UTI. How did this 
risk of UTI affect you and your family?  
 
5. Only in SI groups: 
Your children have all been treated with endoscopic therapy or open 
surgery. How did you experience these interventions?  
6. Children with hVUR sometimes have kidney damage from start and the 
goal of all treatment is to prevent new damages and progress of old. 
How did this risk of renal damage affect you as parents? 
7. Now we would like to learn more about your experiences of the health 
care system; the provision of service, information and accessibility.  
What parts of the health care did you appreciate and what parts can 
be improved? 
8. If this first period in the life of your child has been challenging, how did 
you cope with these challenges? 
9. Lastly, how are you as parents and your child affected by the VUR 
diagnosis today?  
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Demographic data on the informants 
Focus group participants Value 
Mother   13 
Father 6 
Age (years) 25-44 
Number of children per family 1-4  
Marital status:                          
Married 
Cohabitant 
 
9 
10 
Country of birth Sweden 
Place of residence:                  
Large city 
Small town 
Countryside 
 
7 
4 
8 
Parent is healthy:                  
Yes 
No 
 
16 
3 
Education:                           
High school 
University 
Not finished 
 
8 
8 
1 
Occupation:                       
Full-time 
Part-time 
Parental leave part-time 
Sick leave 
 
7 
4 
4 
2 
Content with level of occupation: 
Yes 
Would like to work more 
Would like to work less 
 
11 
3 
2 
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